<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation) - Ostinelli, EG - 2018 | Cochrane Library</title> <meta content="Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation) - Ostinelli, EG - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008074.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation) - Ostinelli, EG - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008074.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008074.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation)" name="citation_title"/> <meta content="Edoardo G Ostinelli" name="citation_author"/> <meta content="Università degli Studi di Milano" name="citation_author_institution"/> <meta content="eg.ostinelli@gmail.com" name="citation_author_email"/> <meta content="Salwan Jajawi" name="citation_author"/> <meta content="Rotherham, Doncaster and South Humber NHS Trust" name="citation_author_institution"/> <meta content="Styliani Spyridi" name="citation_author"/> <meta content="Kamlaj Sayal" name="citation_author"/> <meta content="Cygnet Hospital Derby" name="citation_author_institution"/> <meta content="Mahesh B Jayaram" name="citation_author"/> <meta content="Melbourne Neuropsychiatry Centre" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD008074.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008074.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008074.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008074.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aggression [*drug effects, psychology]; Antipsychotic Agents [*administration &amp; dosage, adverse effects]; Aripiprazole [*administration &amp; dosage, adverse effects]; Benzodiazepines [administration &amp; dosage]; Haloperidol [administration &amp; dosage]; Injections, Intramuscular; Olanzapine; Psychomotor Agitation [*drug therapy, psychology]; Randomized Controlled Trials as Topic; Tranquilizing Agents [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008074.pub2&amp;doi=10.1002/14651858.CD008074.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008074\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008074\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008074.pub2",title:"Aripiprazole (intramuscular) for psychosis\\u2010induced aggression or agitation (rapid tranquillisation)",firstPublishedDate:"Jan 8, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008074.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008074.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008074.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008074.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008074.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008074.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008074.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008074.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008074.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008074.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5158 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008074.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-sec-0214"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-sec-0107"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-sec-0190"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/appendices#CD008074-sec-0226"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/table_n/CD008074StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/table_n/CD008074StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information#CD008074-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Edoardo G Ostinelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information#CD008074-cr-0003">Salwan Jajawi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information#CD008074-cr-0004">Styliani Spyridi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information#CD008074-cr-0005">Kamlaj Sayal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information#CD008074-cr-0006">Mahesh B Jayaram</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information/en#CD008074-sec-0232">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008074.pub2">https://doi.org/10.1002/14651858.CD008074.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008074-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008074-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008074-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008074-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008074-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008074-abs-0001" lang="en"> <section id="CD008074-sec-0001"> <h3 class="title" id="CD008074-sec-0001">Background</h3> <p>People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations. </p> </section> <section id="CD008074-sec-0002"> <h3 class="title" id="CD008074-sec-0002">Objectives</h3> <p>To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis‐induced aggression or agitation (rapid tranquillisation). </p> </section> <section id="CD008074-sec-0003"> <h3 class="title" id="CD008074-sec-0003">Search methods</h3> <p>On 11 December 2014 and 11 April 2017, we searched the Cochrane Schizophrenia Group’s Study‐based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. </p> </section> <section id="CD008074-sec-0004"> <h3 class="title" id="CD008074-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) that randomised people with psychosis‐induced aggression or agitation to receive either intramuscular aripiprazole or another intramuscular intervention. </p> </section> <section id="CD008074-sec-0005"> <h3 class="title" id="CD008074-sec-0005">Data collection and analysis</h3> <p>We independently inspected citations and, where possible, abstracts, ordered papers and re‐inspected and quality assessed these. We included studies that met our selection criteria. At least two review authors independently extracted data from the included studies. We chose a fixed‐effect model. We analysed dichotomous data using risk ratio (RR) and the 95% confidence intervals (CI). We analysed continuous data using mean differences (MD) and their CIs. We assessed risk of bias for included studies and used GRADE to create 'Summary of findings' tables. </p> </section> <section id="CD008074-sec-0006"> <h3 class="title" id="CD008074-sec-0006">Main results</h3> <p>Searching found 63 records referring to 21 possible trials. We could only include three studies, all completed over the last decade, with 885 participants, of which 707 were included for quantitative analyses in this systematic review. Due to limited comparisons, small size of trials and a paucity of investigated and reported 'pragmatic' outcomes, evidence was mostly graded as low or very low quality. No trials reported useful data for one of our primary outcomes of tranquil or asleep by 30 minutes. Economic outcomes were also not reported in the trials. </p> <p>When compared with placebo, fewer people in the aripiprazole group needed additional injections compared to the placebo group (2 RCTs, n = 382, RR 0.69, 95% CI 0.56 to 0.85, <i>very low‐quality evidence</i> ). Clinically important improvement in agitation at two hours favoured the aripiprazole group (2 RCTs, n = 382, RR 1.50, 95% CI 1.17 to 1.92, <i>very low‐quality evidence</i> ). The numbers of non‐responders after the first injection also favoured aripiprazole (1 RCT, n = 263, RR 0.49, 95% CI 0.34 to 0.71, <i>low‐quality evidence</i> ). Although no effect was found, more people in the aripiprazole compared to the placebo group experienced adverse effects (1 RCT, n = 117, RR 1.51, 95% CI 0.93 to 2.46, <i>very low‐quality evidence</i>). </p> <p>Aripiprazole required more injections compared to haloperidol (2 RCTs, n = 477, RR 1.28, 95% CI 1.00 to 1.63, <i>very low‐quality evidence</i> ), with no significant difference in agitation (2 RCTs, n = 477, RR 0.94, 95% CI 0.80 to 1.11, <i>very low‐quality evidence</i> ), and similar non‐responders after first injection (1 RCT, n = 360, RR 1.18, 95% CI 0.78 to 1.79, <i>low‐quality evidence</i> ). Aripiprazole and haloperidol did not differ when taking into account the overall number of people that experienced at least one adverse effect (1 RCT, n = 113, RR 0.91, 95% CI 0.61 to 1.35, <i>very low‐quality evidence</i>). </p> <p>Compared to aripiprazole, olanzapine was better at reducing agitation (1 RCT, n = 80, RR 0.77, 95% CI 0.60 to 0.99, <i>low‐quality evidence</i> ) and had a more favourable effect on global state change scores (1 RCT, n = 80, MD 0.58, 95% CI 0.01 to 1.15, <i>low‐quality evidence</i> ), both at two hours. No differences were found in terms of experiencing at least one adverse effect during the 24 hours after treatment (1 RCT, n = 80, RR 0.75, 95% CI 0.45 to 1.24, <i>very low‐quality evidence</i> ). However, participants allocated to aripiprazole experienced less somnolence (1 RCT, n = 80, RR 0.25, 95% CI 0.08 to 0.82, <i>low‐quality evidence</i>). </p> </section> <section id="CD008074-sec-0007"> <h3 class="title" id="CD008074-sec-0007">Authors' conclusions</h3> <p>The available evidence is of poor quality but there is some evidence aripiprazole is effective compared to placebo and haloperidol, but not when compared to olanzapine. However, considering that evidence comes from only three studies, caution is required in generalising these results to real‐world practice. This review firmly highlights the need for more high‐quality trials on intramuscular aripiprazole in the management of people with acute aggression or agitation. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008074-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008074-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008074-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008074-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008074-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008074-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008074-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008074-abs-0004" lang="en"> <h3>How effective is aripiprazole for calming people who are aggressive or agitated due to psychosis? </h3> <p><b>Background</b><br/> People with psychosis may experience hearing voices (hallucinations) or abnormal thoughts (delusions) which can make them frightened, distressed and agitated (restless, excitable or irritable). Experiencing such emotions can sometimes result in behaviour that is aggressive or violent. This poses a challenge and dilemma for mental health professionals who have to diagnose and, often quickly, give the best available treatment to prevent those who are aggressive, harming themselves or others. </p> <p>Aripiprazole is a medication that can be used to treat psychosis and also calm people who are aggressive or agitated due to psychosis. It can be taken by mouth or by injection (intramuscular). However, aripiprazole can also cause unpleasant side effects such as headaches, upset stomach, and excessive sleepiness or drowsiness. </p> <p>This review looks for evidence from randomised controlled trials that assesses the effectiveness of intramuscular aripiprazole for people who are agitated and aggressive as a result of having psychosis. </p> <p><i>Searching</i><br/> The Information Specialist of the Cochrane Schizophrenia group ran an electronic search in 2014 and in 2017 for studies randomising adults with aggression due to psychosis to receive either injections of aripiprazole or injections of a placebo (dummy treatment) or injections of another antipsychotic. The search found 63 relevant records, referring to 21 trials. Review authors screened these records for inclusion or exclusion. </p> <p><i>Main results</i><br/> Only three studies could be included. Evidence is limited due to the small number of trials and poor quality of data reported. Fewer people receiving aripiprazole required more injections to become calm than those receiving placebo or haloperidol. Overall, aripiprazole caused a similar number of adverse effects to placebo or haloperidol. Compared to olanzapine, aripiprazole was less effective at calming people but caused less sleepiness or drowsiness </p> <p><i>Conclusions</i><br/> Some evidence is available, but is of poor quality, and it is difficult to make conclusions about aripiprazole's effectiveness from such data. Health professionals and people with mental health problems are therefore left without clear guidance concerning use of aripiprazole as a rapid tranquilliser. More research is needed to help people consider which medication is better at calming people down, has fewer adverse effects, and works quickly and rapidly. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008074-sec-0214" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008074-sec-0214"></div> <h3 class="title" id="CD008074-sec-0215">Implications for practice</h3> <section id="CD008074-sec-0215"> <section id="CD008074-sec-0216"> <h5 class="title">1. For people with aggression or aggression induced by psychosis</h5> <p>For people experiencing psychosis‐induced aggression or agitation, or side effects related to acute tranquillisation, a justification for their treatment choice may be helpful when they have recovered. It would be reassuring and informative to be presented with evidence‐based treatment options, should they suffer from similar symptoms in the future. Evidence on the intramuscular use of aripiprazole for agitation or aggression in psychosis in the acute setting is limited. According to the evidence reported in this review, aripiprazole was found to be more effective and with less side effects compared to placebo. In comparison to haloperidol, aripiprazole was found to be overall comparable in tranquillisation, even though data are poor and evidence is weak. Aripiprazole was found to be more prone to cause nausea, with less movement disorders side effects compared to haloperidol. In comparison to olanzapine, aripiprazole was found to be less effective in tranquillisation but less prone to cause somnolence. Patients preference and best interest should be taken into consideration in treatment decision‐making and evidence provided by this review could support a more ethical approach to this matter. </p> </section> <section id="CD008074-sec-0217"> <h5 class="title">2. For clinicians</h5> <p>Aggression or agitation due to psychosis is a difficult situation for clinicians, and, at present, limited evidence of very low to low quality exists for intramuscular treatment with atypical antipsychotics. In this review, the superiority of aripiprazole in comparison to placebo but not haloperidol is reported. Concerning the last comparison, people allocated to aripiprazole required more injections, a potentially complex issue to manage in an acute real‐world setting; whilst experiencing nausea was more common to participants in the aripiprazole group, haloperidol tended to cause more extrapyramidal symptoms side effects. Olanzapine was found to be more effective than aripiprazole, and tended to cause more somnolence side effects. Evidence is limited by the small number of trials available. Further good‐quality research is needed to confirm these results and to provide missing but clinically relevant outcomes, as well as to compare aripiprazole with other atypical antipsychotics (see <a href="#CD008074-tbl-0005">Table 2</a>). </p> <div class="table" id="CD008074-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for a trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, clearly described, concealed.<br/> Blindness: double, described and tested.<br/> Duration: 2 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: thought to be psychoses.<br/> N = 300.*<br/> Age: any.<br/> Sex: both. </p> <p>History: acutely ill, aggressive and/or agitated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Aripiprazole IM: dose flexible within recommended limits. N = 150.<br/> 2. Haloperidol IM: dose flexible within recommended limits. N = 150. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All outcomes are grouped by time: by 30 minutes, up to two hours, up to four hours, up to 24 hours, and over 24 hours. </p> <p>Tranquillisation or asleep ‐ tranquil; asleep.</p> <p>Repeated need for tranquillisation ‐ needing additional injections.<br/> Specific behaviours ‐ self‐harm, including suicide, injury to others.<br/> Global outcomes ‐ patient satisfaction; use of restraint or seclusion.<br/> Service outcomes ‐ length of hospitalisation; readmission rate.<br/> Mental state ‐ effect of medication on mental state.<br/> Adverse effects ‐ medication significant side effects.<br/> Leaving the study early ‐ detailed reasons provided. </p> <p>Quality of life outcomes.<br/> Economic outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜20% between groups for primary outcome with adequate degree of certainty </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IM: intramuscular</p> </div> </div> </section> <section id="CD008074-sec-0218"> <h5 class="title">3. For policy makers</h5> <p>Although atypical antipsychotics such as aripiprazole are theoretically safer and better tolerated compared to haloperidol, this is not clear for people with aggression or agitation due to psychosis. There is evidence that aripiprazole administered intramuscularly is effective for this group of people. However its superiority to haloperidol and olanzapine is not shown, particularly in terms of need for repeated injections for the former and PANSS (Excited Component (PEC) response rate for the latter. Further research with more independent trials is required to form clearer guidelines for people suffering from psychosis‐induced aggression or agitation. </p> </section> </section> <h3 class="title" id="CD008074-sec-0219">Implications for research</h3> <section id="CD008074-sec-0219"> <section id="CD008074-sec-0220"> <h5 class="title">1. General</h5> <p>The Consolidated Standards of Reporting Trials (CONSORT, <a href="./references#CD008074-bbs2-0073" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomised trials. Lancet2001;357(9263):1191‐4. ">Moher 2001</a>) should now be met by all the studies. The protocol, the method, the analysis and the interpretation as well as the assessment of the results validity should be enabled by clearer and more transparent reporting of randomised controlled trials. Specific figures and their measure of variance should be clearly reported in the main text when data are presented in graphs. </p> </section> <section id="CD008074-sec-0221"> <h5 class="title">2. Specific</h5> <section id="CD008074-sec-0222"> <h6 class="title">2.1 Reviews</h6> <p>We have included neither studies of <i>oral</i> use of aripiprazole for management of people with acute aggression or agitation, nor studies that combined aripiprazole with other drugs. It might be possible to update this review with these data. Other reviews relevant to people who are aggressive in combination with psychosis are suggested by the comparisons in the excluded studies. Although some of the excluded studies do find a ready 'home' in already existing reviews or protocols, several do not and potentially neglected and important titles are suggested (<a href="#CD008074-tbl-0006">Table 3</a>). </p> <div class="table" id="CD008074-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Additional reviews relevant to aggression and suggested from excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Aripiprazole</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Combination</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison #1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison #2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Suggested title of review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cochrane review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aripiprazole + olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>quetiapine + olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0018" title="王琦 , 周丹 , 李萍 , 谢红涛 . 非典型抗精神病药对精神分裂症患者激越行为的随机对照研究. 中国健康心理学杂志2014;22(3):325‐7. ">Wang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipsychotic combinations for psychosis‐induced aggression or agitation (rapid tranquillisation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long acting (441mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long acting (882 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0014" title="CitromeL , DuY , RisingerR , StankovicS , ClaxtonA , ZummoJ , et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology2016;31(2):69‐75. CitromeL , DuY , RisingerR , StankovicS , ClaxtonA , ZummoJ , et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia: Erratum. International Clinical Psychopharmacology2017;32(1):56. HardM , StankovicS , RisingerR , BoseA , DuY , ZummoJ , et al. Efficacy of aripiprazole lauroxil, a new long‐acting injectable atypical antipsychotic, across three geographic regions. Neuropsychopharmacology2014;39:S359‐60. MeltzerHY , NasrallahHA , RisingerR , DuY , ZummoJ , CoreyL , et al. Aripiprazole lauroxil: an innovative long‐acting injectable in development for treatment of schizophrenia. 168th Annual Meeting of American Psychiatric Association; Toronto, Canada; May 16‐20, 2015. 2015. MeltzerHY , RisingerR , NasrallahHA , DuY , ZummoJ , CoreyL , et al. A randomized, double‐blind, placebo‐controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. Journal of Clinical Psychiatry2015;76(8):1085‐90. NCT01469039 . A study to evaluate the efficacy and safety of alks 9072 (also known as alks 9070) in subjects with schizophrenia. http://ClinicalTrials.gov/show/NCT014690392011. NasrallahHA , NewcomerJW , RisingerR , DuY , ZummoJ , BoseA , et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. Journal of Clinical Psychiatry2016;77(11):1519‐25. TargumSD , RisingerR , DuY , PendergrassJC , JamalHH , SilvermanBL . Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia [2017 Jan;179:64‐69.]. Schizophrenia Research2017;179:64‐9. ">NCT0146903</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole for long‐term aggression in psychosis; Placebo for long‐term aggression in psychosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aripiprazole + magnesium valproate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0010" title="李树生 . Aripiprazole for schizophrenia combined magnesium valproate efficacy of impulse control disorders] Google Translate [阿立哌唑联合丙戊酸镁对精神分裂症冲动控制障碍的疗效观察]. Chongqing Medical Journal2009;38(7):788‐9. ">Li 2009</a>, <a href="./references#CD008074-bbs2-0012" title="刘杰 . 丙戊酸镁对精神分裂症兴奋激越行为的辅助疗效观察. 社区医学杂志2012;10(14):31‐2. ">Liu 2012</a>, <a href="./references#CD008074-bbs2-0019" title="颉瑞 , 王刚平 , 裴根祥 . Clinical observation of magnesium valproate sustained release tablets adjuvant treatment of schizophrenia attacks [丙戊酸镁缓释片辅助治疗精神分裂症攻击行为的疗效观察]. 临床精神医学杂志2011;21(03):191‐2. ">Xie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium valproate (+/‐aripiprazole) for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oral olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0005" title="陈远岭 , 黄文武 , 叶鑫武 . Aripiprazole treatment of agitation associated with schizophrenia] Google Translate [阿立哌唑治疗伴激越的精神分裂症对照研究 []. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(4):261‐2. ">Chen 2009</a>, <a href="./references#CD008074-bbs2-0009" title="EliLilly , Company . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry2004. KinonBJ , StaufferVL , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(6):601‐7. [MEDLINE: 19011427] NCT00103571 . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. http://www.clinicaltrials.gov2005. StaufferV , KinonB , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8, Washington DC, USA. 2008. [NR4‐109] ">Kinon 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole (oral) for psychosis‐induced aggression or agitation (rapid tranquillisation); Olanzapine (oral) for psychosis‐induced aggression or agitation (rapid tranquillisation); </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>? expansion of this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oral clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0004" title="BaoL‐Y , WangK‐M . The effectiveness of aripirazole combined with clonazepam treated with agitation in schizophrenia. Medical Journal of Chinese People's Health2007;19(3):198‐200. [CHINESE: Academic Journals] ">Bao 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole plus benzodiazepines for psychosis‐induced aggression or agitation (rapid tranquillisation); Clozapine for psychosis‐induced aggression or agitation (rapid tranquillisation); </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>? expansion of this review; <a href="./references#CD008074-bbs2-0091" title="ToalF , RobertsK . Clozapine for people with psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012. ">Toal 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Non‐aripiprazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IM haloperidol + lorazepam + benztropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oral quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0016" title="SimpsonG , MohammadAR , FauziaS , CampaneauM , LaskaE , NinahR , et al. A comparison of rapid titration quetiapine and haloperidol in agitated adults in an emergency setting. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. ">Simpson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzodiazepines for psychosis‐induced aggression or agitation (rapid tranquillisation); Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation); Quetiapine for psychosis‐induced aggression or agitation (rapid tranquillisation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0050" title="GilliesD , SampsonS , BeckA , RathboneJ . Benzodiazepines for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003079.pub3] ">Gillies 2015</a>;<a href="./references#CD008074-bbs2-0079" title="OstinelliEG , Brooke‐PowneyMJ , LiX , AdamsCE . Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews2017, Issue 7. [DOI: 10.1002/14651858.CD009377.pub3] ">Ostinelli 2017</a>;<a href="./references#CD008074-bbs2-0094" title="WilkieF , FentonM . Quetiapine for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009801] ">Wilkie 2012</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* One sub‐study with people with aggression/agitation.</p> </div> </div> </section> <section id="CD008074-sec-0223"> <h6 class="title">2.2 Trials</h6> <p>This review is the result of research over the last decade on the use of aripiprazole IM for aggression or agitation induced by psychosis. More large independent randomised trials are required to measure 'pragmatic' outcomes, such as 'tranquillisation or asleep' outcomes within multiple time points during the first two hours, or economic outcomes. This type of randomised controlled trial should be provided with high‐quality methodological design, measuring simple outcomes such as those indicated in <a href="#CD008074-tbl-0005">Table 2</a>. These studies just need modest financial support and firm help from ethics committees who understand the need to produce good evidence for practice in this difficult edge of health care. </p> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008074-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008074-sec-0022"></div> <div class="table" id="CD008074-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to PLACEBO/NIL for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARIPIPRAZOLE compared to PLACEBO/NIL for psychosis‐induced aggression or agitation (rapid tranquillisation)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychosis‐induced aggression or agitation (rapid tranquillisation)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> ARIPIPRAZOLE (intramuscular)<br/> <b>Comparison:</b> PLACEBO/NIL </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PLACEBO/NIL</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ARIPIPRAZOLE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Repeated need for tranquillisation</b> ‐ needing additional injections during 24 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.69<br/> (0.56 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>382<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1.000<br/> (140 to 213) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414 per 1.000<br/> (336 to 510) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>518 per 1.000<br/> (420 to 638) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Specific behaviour:</b> Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 1.50<br/> (1.17 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>382<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1.000<br/> (117 to 192) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1.000<br/> (410 to 672) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1.000<br/> (819 to 1.000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state:</b> non‐responders to the first injection </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.49<br/> (0.34 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>263<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1.000<br/> (68 to 142) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221 per 1.000<br/> (153 to 320) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1.000<br/> (238 to 497) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects:</b> one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.51<br/> (0.93 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1.000<br/> (274 to 726) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'serious' (downgraded by 1) ‐ randomisation procedure is not reported for both the included studies, and allocation concealment procedure is not consistently reported in <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>. While for the 'randomisation' bias, studies are at least reported as 'randomised', as for the latter that allocation concealment was correctly handled could not be implied. </p> <p><sup>2</sup> Indirectness: rated 'very serious' (downgraded by 2) ‐ participants included in the studies had levels of agitation not so pronounced by inclusion criteria, potentially under‐estimating or more likely over‐estimating true effectiveness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008074-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: a. HALOPERIDOL for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARIPIPRAZOLE compared to OTHER ANTIPSYCHOTIC: a. HALOPERIDOL for psychosis‐induced aggression or agitation (rapid tranquillisation)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychosis‐induced aggression or agitation (rapid tranquillisation)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> ARIPIPRAZOLE (intramuscular)<br/> <b>Comparison:</b> OTHER ANTIPSYCHOTIC: a. HALOPERIDOL </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ARIPIPRAZOLE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Repeated need for tranquillisation</b> ‐ needing additional injections during 24 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 1.28<br/> (1.00 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>477<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>,</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1.000<br/> (100 to 163) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>384 per 1.000<br/> (300 to 489) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>640 per 1.000<br/> (500 to 815) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Specific behaviour</b>: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.80 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>477<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 ,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>576 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1.000<br/> (460 to 639) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state</b>: non‐responders to the first injection </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.78 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1.000<br/> (143 to 329) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects</b>: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.61 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>113<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>491 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1.000<br/> (300 to 663) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects</b>: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.29<br/> (0.12 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>471<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1.000<br/> (6 to 35) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1.000<br/> (12 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1.000<br/> (36 to 210) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'serious' (downgraded by 1) ‐ randomisation procedure is not reported for both the included studies, and allocation concealment procedure is not consistently reported in <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>. While for the 'randomisation' bias studies are at least reported as 'randomised', as for the latter that allocation concealment was correctly handled could not be implied. </p> <p><sup>2</sup> Indirectness: rated 'very serious' (downgraded by 2) ‐ participants included in the studies had levels of agitation not so pronounced by inclusion criteria, potentially under‐estimating or more likely over‐estimating true effectiveness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008074-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARIPIPRAZOLE compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE for psychosis‐induced aggression or agitation (rapid tranquillisation)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychosis‐induced aggression or agitation (rapid tranquillisation)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> ARIPIPRAZOLE (intramuscular)<br/> <b>Comparison:</b> OTHER ANTIPSYCHOTIC: b. OLANZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with OTHER ANTIPSYCHOTIC: b. OLANZAPINE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ARIPIPRAZOLE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Repeated need for tranquillisation</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Specific behaviour:</b> Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.77<br/> (0.60 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1.000<br/> (300 to 495) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>616 per 1.000<br/> (480 to 792) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>693 per 1.000<br/> (540 to 891) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state:</b> CGI‐S change score up to 2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.58<br/> (0.01 higher to 1.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects:</b> one or more adverse effects during 24 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/> (0.45 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1.000<br/> (225 to 620) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects:</b> somnolence during 24 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.25<br/> (0.08 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1.000<br/> (8 to 82) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1.000<br/> (24 to 246) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1.000<br/> (56 to 574) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Imprecision ‐ rated 'serious' (downgraded by 1): Optimal Information Size (OIS) criterion is not met meaning that imprecision of effect estimates could not be properly handled. </p> <p><sup>2</sup> Imprecision ‐ rated 'very serious' (downgraded by 2): Optimal Information Size (OIS) criterion is not met and CI overlaps no effect. High imprecision of effect estimates could not be properly excluded. </p> <p><sup>3</sup> Indirectness ‐ rated 'serious' (downgraded by 1): attribution to the intervention drugs is suspected but can not be confirmed since in the study results it is showed that almost all the participants were administered with 'treatment as usual' drugs. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008074-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008074-sec-0023"></div> <section id="CD008074-sec-0024"> <h3 class="title" id="CD008074-sec-0024">Description of the condition</h3> <p>Aggression and agitation are psychiatric emergencies that can often be associated with psychosis, substance misuse or epilepsy (<a href="./references#CD008074-bbs2-0089" title="TardiffK , SweillamA . Assaultive behavior among chronic inpatients. American Journal of Psychiatry1982;139(2):212‐5. ">Tardiff 1982</a>). Aggression is described as hostile, injurious, or destructive behaviour, and can occur in about 3% of psychiatric outpatients (<a href="./references#CD008074-bbs2-0090" title="TardiffK , KoenigsbergHW . Assaultive behavior among psychiatric outpatients. American Journal of Psychiatry1985;142:960‐3. ">Tardiff 1985</a>) and in up to 7% to 10% of inpatient settings. Agitation is described as a state of troubled mind or feelings (<a href="./references#CD008074-bbs2-0070" title="MakinsM . Collins Compact English Dictionary. 3rd Edition. Glasgow: Harpercollins Publishers, 1994:15. ">Makins 1994</a>) and is characterised by restlessness, excitability and irritability, and for some people, this can result in verbal and physical aggressive behaviour (<a href="./references#CD008074-bbs2-0074" title="MohrP , PecenakJ , SvestkaJ , SwinglerD , TreuerT . Treatment of acute agitation in psychotic disorders. Neuro Endocrinology Letters2005;26(4):327‐35. ">Mohr 2005</a>). As is often the case, patients experiencing these episodes find new environments stressful and become aggressive (<a href="./references#CD008074-bbs2-0048" title="FerracutiS , PalermoGB , ManfrediM . Homicide between inpatients in a mental institution ward. International Journal of Offender Therapy and Comparative Criminology1993;37:331‐7. ">Ferracuti 1993</a>). Aggression and agitation within the psychiatric setting imposes a significant challenge to clinicians who, while attempting to make an accurate diagnosis and formulation (<a href="./references#CD008074-bbs2-0083" title="SchleiferJJ . Management of acute agitation in psychosis: an evidence‐based approach in the USA. Advances in Psychiatric Treatment2011;17:91‐100. ">Schleifer 2011</a>), have to intervene quickly in order to manage the risk that the service user may present to themselves, other service users and staff (<a href="./references#CD008074-bbs2-0078" title="National Institute for Clinical Excellence. Violence and aggression: short‐term management in mental health, health and community settings. nice.org.uk/guidance/ng102015. ">NICE 2015</a>). </p> <p>There have been numerous national and international guidelines that created protocols for managing people with aggression and violence (<a href="./references#CD008074-bbs2-0027" title="American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd Edition. Practice guideline for the treatment of patients with schizophrenia2006. ">APA 2006</a>; <a href="./references#CD008074-bbs2-0037" title="AddingtonD , BouchardRH , GoldbergJ , HonerB , MallaA , NormanR , et al. Clinical practice guidelines: Treatment of schizophrenia. Canadian Journal of Psychiatry2005;50(Suppl 1):3S‐56S. ">CPA 2005</a>; <a href="./references#CD008074-bbs2-0078" title="National Institute for Clinical Excellence. Violence and aggression: short‐term management in mental health, health and community settings. nice.org.uk/guidance/ng102015. ">NICE 2015</a>). Some evidence from these guidelines may be conflicting in nature. For example, the use of zuclopenthixol acetate is not recommended by NICE, but recommended by Australian and Canadian guidelines. This is not surprising as there has only been one trial of zuclopenthixol acetate in this area and the small sample size from this trial could lead to varied interpretations. An individual requiring rapid tranquillisation is frequently unable or unwilling to consent and the treatment is being provided in his or her best interest. </p> <p>In the UK, NICE guidelines recommend that a comprehensive risk assessment is the first step in management of aggression and non‐pharmacological methods recommended for use include de‐escalation, physical restraints and seclusion. Where rapid tranquillisation through oral therapy is refused, is not indicated by previous clinical response, is not a proportionate response, or is ineffective, administration of an intramuscular combination of haloperidol and promethazine or intramuscular lorazepam is recommended (<a href="./references#CD008074-bbs2-0078" title="National Institute for Clinical Excellence. Violence and aggression: short‐term management in mental health, health and community settings. nice.org.uk/guidance/ng102015. ">NICE 2015</a>). </p> <p>In the USA, the first intervention involves staff members talking to the patient in an attempt to calm him or her. Attempts to restrain the patient should be done only by a team trained in safe restraint procedures to minimise risk of harm to patients or staff. Antipsychotics and benzodiazepines are often helpful in reducing the patient’s level of agitation. If the patient will take oral medication, rapidly dissolving forms of olanzapine and risperidone can be used for quicker effect and to reduce non adherence. If a patient refuses oral medication, most states allow for emergency administration despite the patient’s objection. Short‐acting parenteral formulations of first‐ and second‐generation antipsychotic agents (e.g. haloperidol, ziprasidone, and olanzapine), with or without a parenteral benzodiazepine (e.g. lorazepam), are available for emergency administration in acutely agitated patients (<a href="./references#CD008074-bbs2-0027" title="American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd Edition. Practice guideline for the treatment of patients with schizophrenia2006. ">APA 2006</a>). </p> <p>There have been only a handful of surveys looking at the prevalence and practices in managing acute agitation. <a href="./references#CD008074-bbs2-0038" title="CunnaneJG . Drug management of disturbed behaviour by psychiatrists. Psychiatric Bulletin1994;18(3):138‐9. ">Cunane 1994</a> found that in the UK, clinicians preferred using chlorpromazine, whereas <a href="./references#CD008074-bbs2-0030" title="BinderRL , McNielDE . Contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatric Services1999;50(12):1553‐4. ">Binder 1999</a> found that in the USA, clinicians preferred a combination of haloperidol and benzodiazepines. In a more recent survey, <a href="./references#CD008074-bbs2-0056" title="HufG , CoutinhoESF , FagundesHMJr , OliveiraES , LopezJRRA , GewandszajderM , et al. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro‐Brazil: a prevalence study. BMC Psychiatry2002;2(4):1‐6. ">Huf 2002a</a> found that Brazilian psychiatrists preferred a combination of haloperidol and promethazine. Surveys of this nature are notoriously difficult to conduct specially in resource‐poor settings, which partly explains the paucity of such surveys from low‐income countries. There have been a few good quality pragmatic trials comparing various interventions such as haloperidol, olanzapine, promethazine, benzodiazepines including lorazepam and midazolam, and other medications for managing acute agitation (<a href="./references#CD008074-bbs2-0025" title="AlexanderJ , TharyanP , AdamsCE , JohnT , MolC , PhilipJ . Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. British Journal of Psychiatry2004;185:63‐9. ">Alexander 2004</a>; <a href="./references#CD008074-bbs2-0057" title="HufG , CoutinhoESF , AdamsCE . TREC‐Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry2002;2(11):1‐12. ">Huf 2002b</a>; <a href="./references#CD008074-bbs2-0081" title="RaveendranNS , TharyanP , AlexanderJ , Adams CE and the TREC‐India II Collaborative Group. Rapid tranquilization of violent or agitated people in psychiatric emergency settings: A pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJOCT 2007;335(7265):865‐72. ">Raveendran 2007</a>). </p> </section> <section id="CD008074-sec-0025"> <h3 class="title" id="CD008074-sec-0025">Description of the intervention</h3> <p>Aripiprazole is a quinolinone derivative, 7‐[4‐[4‐(2,3‐dichlorophenyl)‐1‐piperazinyl]butoxy]‐3,4‐dihydrocarbostyril (<a href="./references#CD008074-bbs2-0065" title="KikuchiT , TottoriK , UwahodoY , HiroseT , MiwaT , OshiroY , et al. 7‐(4‐[4‐(2,3‐Dichlorophenyl)‐1‐piperazinyl]butyloxy)‐3,4‐dihydro‐2(1H)‐quinolinone (OPC‐14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Journal of Pharmacology and Experimental Therapeutics1995;274(1):329‐36. ">Kikuchi 1995</a>; <a href="#CD008074-fig-0001">Figure 1</a>). It is available as oral tablets, orally disintegrating tablets, oral solution and intramuscular injections. The intramuscular preparations are available in single‐dose vials as a ready‐to‐use, 9.75 mg/1.3 mL (7.5 mg/mL) clear, colourless, sterile, aqueous solution. Inactive ingredients for this solution include 150 mg/mL of sulfobutylethercyclodextrin (SBECD), tartaric acid, sodium hydroxide and water for injection (<a href="./references#CD008074-bbs2-0022" title="Abilify (Aripiprazole). US full prescribing information. http://otsuka‐us.com/products/Documents/Abilify.PI.pdf?_ga=1.242215874.1724823722.1491413596 (accessed 5 April 2017). ">Abilify 2017</a>). Intramuscular aripiprazole seems to have two medians for peak plasma concentrations, one at one hour and the second at three hours. It has 100% bioavailability and the pharmacokinetics is linear over a dose range of 1 mg to 45 mg. It is likely to be eliminated by the liver using the P450 system of isoenzymes (CYP2D6 and CYP3A4, <a href="./references#CD008074-bbs2-0022" title="Abilify (Aripiprazole). US full prescribing information. http://otsuka‐us.com/products/Documents/Abilify.PI.pdf?_ga=1.242215874.1724823722.1491413596 (accessed 5 April 2017). ">Abilify 2017</a>). </p> <div class="figure" id="CD008074-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Aripiprazole structure" data-id="CD008074-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Aripiprazole structure</p> </div> </div> </div> <p>Aripiprazole solution, for injection, is licensed for rapid control of agitation and disturbed behaviours in adults when oral therapy is not appropriate. The dose for adults is 9.75 mg (1.3 mL) as a single intramuscular injection initially with an effective dose range of 5.25 mg to 15 mg as a single injection. Second injections can be administered two hours after the first, No more than three injections should be given in any 24‐hour period. </p> </section> <section id="CD008074-sec-0026"> <h3 class="title" id="CD008074-sec-0026">How the intervention might work</h3> <p>According to treatment guidelines, aripiprazole is classified amongst the second‐generation antipsychotics with amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine. However, aripiprazole has been described as the prototype of a new and third generation of antipsychotics, the so called 'dopamine‐serotonin system stabilisers' (<a href="./references#CD008074-bbs2-0072" title="McGavinJK , GoaKL . Aripiprazole. CNS Drugs2002;16(11):779‐86. ">McGavin 2002</a>; <a href="./references#CD008074-bbs2-0088" title="Swainston HarrisonT , PerryCM . Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs2004;64(15):1715‐36. ">Swainston Harrison 2004</a>). </p> <p>It is reported to exert its antipsychotic effects by acting as a partial agonist at dopamine D2 and 5‐HT1A receptors and antagonist activity at 5‐HT2A receptors (<a href="./references#CD008074-bbs2-0085" title="ShapiroDA , RenockS , ArringtonE , ChiodoLA , LiuLX , SibleyDR , et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology2003;28(8):1400‐11. ">Shapiro 2003</a>). It has been postulated that through dopamine and serotonin system stabilisation, a partial D2 agonist would be able to act as an antagonist in pathways where an abundance of dopamine was leading to 'psychosis', yet it would stimulate receptors as an agonist at sites in which low‐dopaminergic tone would produce adverse effects. </p> <p>Aripiprazole, however, also has an affinity to other receptors including D3, D4, 5‐HT2c, 5HT7, alpha‐1 adrenergic and histamine receptors, which could be related to some adverse effects (such as headache, gastrointestinal upset, headedness, somnolence; <a href="./references#CD008074-bbs2-0047" title="US Federal Drug Administration CDER. Application number: NDA 21‐436/S‐002 (accessed 5 April 2017). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021436Orig1s002.pdf2004. ">FDA 2004</a>). The recommended target dose for aripiprazole is 10 mg to 15 mg per day (dose range 10 mg to 30 mg/day). Phase III trials were initially conducted in Japan in 1995 and the drug was granted Approved Status by the FDA (USA) on the 15 November 2002 for the treatment of schizophrenia. Aripiprazole has since been licensed in most countries worldwide. </p> </section> <section id="CD008074-sec-0027"> <h3 class="title" id="CD008074-sec-0027">Why it is important to do this review</h3> <p>Aripiprazole has been around since 2002 and its use has been gradually increasing in the UK. Recent data state that for aripiprazole the spending on NHS prescriptions in England was about £6m in 2008, about £10m in 2010, rising to £15m in 2013 (<a href="./references#CD008074-bbs2-0077" title="NHS prescription services. http://www.nhsbsa.nhs.uk/prescriptions (accessed 12 December 2014). ">NHS 2014</a>). An intramuscular formulation of aripiprazole has recently been licensed for use in treatment of acute agitation. The increase in prescribing costs of oral aripiprazole seems to be in keeping with the general increase in atypical antipsychotic prescribing in the UK. If previous trends are to go by, we could expect a general increase in cost of intramuscular aripiprazole use to the UK's NHS over the next few years. In terms of raw cost data, there are considerable differences between the older generation and newer generation of antipsychotics. For example, in the UK a vial of haloperidol 5 mg/mL costs 30 pence, a vial of promethazine 25 mg/mL 70 pence, whereas, a vial of olanzapine 5 mg/mL about £3.48, and finally a vial of aripiprazole 9.75 mg costs £3.43 in the UK (<a href="./references#CD008074-bbs2-0032" title="BNF . 4.2.1 Antipsychotic drugs. BNF 67 March‐September 2014. London: BMJ Group AND Pharmaceutical Press, 2014:235. ">BNF 2014</a>). </p> <p>With the increasing number of the antipsychotic medications that are available for intramuscular use and treatment of acute agitation, there is an urgent need to systematically review and evaluate the effects of intramuscular aripiprazole. This is one of a series of similar reviews (<a href="#CD008074-tbl-0004">Table 1</a>). </p> <div class="table" id="CD008074-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other relevant Cochrane reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Focus of review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Completed and maintained reviews</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'As required' medication regimens for seriously mentally ill people in hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0043" title="Douglas‐HallP , WhicherEV . 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database of Systematic Reviews2015, Issue 12. [DOI: 10.1002/14651858.CD003441.pub3] ">Douglas‐Hall 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzodiazepines for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0050" title="GilliesD , SampsonS , BeckA , RathboneJ . Benzodiazepines for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003079.pub3] ">Gillies 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorpromazine for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0023" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2; PUBMED: 20393959] ">Ahmed 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotiapine for acute psychotic illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0029" title="BerkM , RathboneJ , Mandriota‐CarpenterSL . Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2] ">Berk 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Containment strategies for people with serious mental illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0076" title="MuralidharanS , FentonM . Containment strategies for people with serious mental illness. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD002084.pub2] ">Muralidharan 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>De‐escalation techniques for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0044" title="DuM , WangX , YinS , ShuW , HaoR , ZhaoS , et al. De‐escalation techniques for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD009922.pub2; CD009922] ">Du 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol for acute psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0063" title="KhokharMA , RathboneJ . Droperidol for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD002830.pub3] ">Khokhar 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol for long‐term aggression in psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0064" title="KhushuA , PowneyMJ . Haloperidol for long‐term aggression in psychosis. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2016, issue 11. [DOI: 10.1002/14651858.CD009830.pub2; CD009830] ">Khushu 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0079" title="OstinelliEG , Brooke‐PowneyMJ , LiX , AdamsCE . Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews2017, Issue 7. [DOI: 10.1002/14651858.CD009377.pub3] ">Ostinelli 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol plus promethazine for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0058" title="HufG , AlexanderJ , GandhiP , et al. Haloperidol plus promethazine for psychosis‐induced aggression. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD005146.pub3; CD005146] ">Huf 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0028" title="BelgamwarRB , FentonM . Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD003729.pub2] ">Belgamwar 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seclusion and restraint for serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0082" title="SailasE , FentonM . Seclusion and restraint for people with serious mental illnesses. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD001163] ">Sailas 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0060" title="JayakodyK , GibsonRC , KumarA , GunadasaS . Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD000525.pub3] ">Jayakody 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Reviews in the process of being completed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0024" title="AhmedU , RehmanF , JonesH , AdamsCE . Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD009412] ">Ahmed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loxapine inhaler for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0093" title="VangalaR , AhmedU , AhmedR . Loxapine inhaler for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD010190] ">Vangala 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine for people with psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0091" title="ToalF , RobertsK . Clozapine for people with psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012. ">Toal 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0094" title="WilkieF , FentonM . Quetiapine for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009801] ">Wilkie 2012</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008074-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008074-sec-0028"></div> <p>To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis‐induced aggression or agitation (rapid tranquillisation). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008074-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008074-sec-0029"></div> <section id="CD008074-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008074-sec-0031"> <h4 class="title">Types of studies</h4> <p>All relevant randomised control trials. If a trial was described as ’double‐blind’ but implied randomisation, we included such trials in a sensitivity analysis (see <a href="#CD008074-sec-0101">Sensitivity analysis</a>). If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion resulted in statistically significant differences, we did not add the data from these lower‐quality studies to the results of the better trials, but presented such data within a subcategory. We planned to exclude quasi‐randomised studies, such as those allocating by alternate days of the week or where allocation was undertaken on surname. </p> </section> <section id="CD008074-sec-0032"> <h4 class="title">Types of participants</h4> <p>People exhibiting aggression or agitation (or both) thought to be due to psychosis, regardless of age and sex. Should studies have involved people with other diagnoses, such as drug or alcohol intoxication, organic problems including dementia, non‐psychotic mental illnesses or learning disabilities, we would have included these as long as the majority of participants (&gt; 50%) were experiencing psychosis. </p> </section> <section id="CD008074-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD008074-sec-0034"> <h5 class="title">1. Aripiprazole</h5> <p>Given alone, intramuscularly in any dose.</p> <p>versus:</p> </section> <section id="CD008074-sec-0035"> <h5 class="title">A. Other antipsychotic medications</h5> <p>Given alone, intramuscularly in any dose.</p> </section> <section id="CD008074-sec-0036"> <h5 class="title">B. Placebo</h5> <p>Active or non‐active, intramuscular, in any dose.</p> </section> </section> <section id="CD008074-sec-0037"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes grouped by time: by 30 minutes, up to two hours, up to four hours, up to 24 hours, and over 24 hours. </p> <p>We endeavoured to report binary outcomes recording clear and clinically meaningful degrees of change (e.g. global impression of much improved, or more than 50% improvement on a rating scale ‐ as defined within the trials) before any others. Thereafter, we listed other binary outcomes and then those that were continuous. </p> <section id="CD008074-sec-0038"> <h5 class="title">Primary outcomes</h5> <section id="CD008074-sec-0039"> <h6 class="title">1. Tranquil or asleep</h6> <p>1.1 Tranquil or asleep ‐ by up to 30 minutes *</p> </section> <section id="CD008074-sec-0040"> <h6 class="title">2. Repeated need for rapid tranquillisation</h6> </section> </section> <section id="CD008074-sec-0041"> <h5 class="title">Secondary outcomes</h5> <section id="CD008074-sec-0042"> <h6 class="title">1. Tranquillisation or asleep</h6> <p>1.1 Tranquil or asleep ‐ over 30 minutes *<br/> 1.2 Time to tranquillisation/sleep<br/> 1.3 Time to tranquillisation<br/> 1.4 Time to sleep </p> </section> <section id="CD008074-sec-0043"> <h6 class="title">2. Specific behaviours</h6> <p>2.1 Self‐harm, including suicide<br/> 2.2 Injury to others<br/> 2.3 Agitation<br/> 2.3.1 Another episode of agitation by 24 hours<br/> 2.3.2 Clinically important change in agitation *<br/> 2.3.3 Any change in agitation<br/> 2.3.4 Average endpoint score ‐ agitation scales<br/> 2.3.5 Average change score ‐ agitation scales<br/> 2.4 Aggression<br/> 2.4.1 Another episode of aggression by 24 hours<br/> 2.4.2 Clinically important change in aggression *<br/> 2.4.3 Any change in aggression<br/> 2.4.4 Average endpoint score ‐ aggression scales<br/> 2.4.5 Average change score ‐ aggression scales </p> </section> <section id="CD008074-sec-0044"> <h6 class="title">3. Global state</h6> <p>3.1 Overall improvement<br/> 3.2 Use of additional medication<br/> 3.3 Use of restraints/seclusion<br/> 3.4 Relapse ‐ as defined by each study<br/> 3.5 Recurrence of violent incidents<br/> 3.6 Needing extra visits from the doctor<br/> 3.7 Refusing oral medication </p> </section> <section id="CD008074-sec-0045"> <h6 class="title">4. Service use</h6> <p>4.1 Duration of hospital stay<br/> 4.2 Re‐admission<br/> 4.3 Clinically important engagement with services<br/> 4.4 Any engagement with services<br/> 4.5 Average endpoint engagement score<br/> 4.6 Average change in engagement scores </p> </section> <section id="CD008074-sec-0046"> <h6 class="title">5. Mental state</h6> <p>5.1 Clinically important change in general mental state<br/> 5.2 Any change in general mental state<br/> 5.3 Average endpoint general mental state score<br/> 5.4 Average change in general mental state scores </p> </section> <section id="CD008074-sec-0047"> <h6 class="title">6. Adverse effects</h6> <p>6.1 Death<br/> 6.2 Any general adverse effects<br/> 6.3 Any serious specific adverse effects<br/> 6.4 Average endpoint general adverse effect score<br/> 6.5 Average change in general adverse effect scores<br/> 6.6 Clinically important change in specific adverse effects<br/> 6.7 Any change in specific adverse effects<br/> 6.8 Average endpoint specific adverse effects<br/> 6.9 Average change in specific adverse effects </p> </section> <section id="CD008074-sec-0048"> <h6 class="title">7. Leaving the study early</h6> <p>7.1 For specific reasons<br/> 7.2 For general reasons </p> </section> <section id="CD008074-sec-0049"> <h6 class="title">8. Satisfaction with treatment</h6> <p>8.1 Recipient of treatment satisfied with treatment<br/> 8.2 Recipient of treatment average satisfaction score<br/> 8.3 Recipient of treatment average change in satisfaction scores<br/> 8.4 Informal treatment provider satisfied with treatment<br/> 8.5 Informal treatment providers' average satisfaction score<br/> 8.6 Informal treatment providers' average change in satisfaction scores<br/> 8.7 Professional providers satisfied with treatment<br/> 8.8 Professional providers' average satisfaction score<br/> 8.9 Professional providers' average change in satisfaction scores </p> </section> <section id="CD008074-sec-0050"> <h6 class="title">9. Acceptance of treatment</h6> <p>9.1 Accepting treatment<br/> 9.2 Average endpoint acceptance score<br/> 9.3 Average change in acceptance scores </p> </section> <section id="CD008074-sec-0051"> <h6 class="title">10. Quality of life</h6> <p>10.1 Clinically important change in quality of life *<br/> 10.2 Any change in quality of life *<br/> 10.3 Average endpoint quality of life score<br/> 10.4 Average change in quality of life score<br/> 10.5 Clinically important change in specific aspects of quality of life *<br/> 10.6 Any change in specific aspects of quality of life *<br/> 10.7 Average endpoint specific aspects of quality of life<br/> 10.8 Average change in specific aspects of quality of life </p> </section> <section id="CD008074-sec-0052"> <h6 class="title">10. Economic outcomes</h6> <p>10.1 Direct costs<br/> 10.2 Indirect costs </p> </section> <section id="CD008074-sec-0053"> <h6 class="title">Outcomes used for 'Summary of findings' tables</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD008074-bbs2-0084" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>) and used the <a href="https://gradepro.org" target="_blank">GRADEpro GDT</a> web application to export data from this review to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision‐making. We selected the following main outcomes for inclusion in the 'Summary of findings' tables. </p> <p>1. Tranquillisation or asleep ‐ by 30 minutes.<br/> 2. Repeated need for rapid tranquillisation ‐ within 24 hours.<br/> 3. Specific behaviours ‐ agitation or aggression.<br/> 4. Global state ‐ clinically important overall improvement *.<br/> 5. Adverse effects ‐ any serious, specific adverse effects.<br/> 6. Economic outcomes </p> <p>* see <a href="#CD008074-sec-0236">Differences between protocol and review</a> </p> </section> </section> </section> </section> <section id="CD008074-sec-0054"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied within the limitations of the search tools.</p> <section id="CD008074-sec-0055"> <h4 class="title">Electronic searches</h4> <section id="CD008074-sec-0056"> <h5 class="title">Cochrane Schizophrenia Group’s Study‐Based Register of Trials</h5> <p>On 11 December 2014 and 11 April 2017, the Information Specialist searched the register using the following search strategy: </p> <p>(*Aripiprazole*) in Intervention AND (*Aggress* or *Violent* or *Agitation* or *Tranq*) in Healthcare Condition Fields of Study </p> <p>In such study‐based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>This register is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD008074-sec-0057"> <h4 class="title">Searching other resources</h4> <section id="CD008074-sec-0058"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD008074-sec-0059"> <h5 class="title">2. Personal contact</h5> <p>Where necessary, we attempted to contact the first author of each included study for information regarding unpublished trials. </p> </section> </section> </section> <section id="CD008074-sec-0060"> <h3 class="title" id="CD008074-sec-0060">Data collection and analysis</h3> <section id="CD008074-sec-0061"> <h4 class="title">Selection of studies</h4> <p>For the 2014 search, review authors SJ, and KS independently inspected citations from the searches and identified relevant abstracts. A random 20% sample was independently re‐inspected by SS to ensure reliability. Where disputes arose, the full report was acquired for more detailed scrutiny. SJ and KS obtained and inspected full reports of the abstracts meeting the review criteria. If it had not been possible to resolve disagreement by discussion, we would have attempted to contact the authors of the study for clarification. </p> <p>For the 2017 search, review author EGO independently inspected citations and identified relevant abstracts. EGO also re‐inspected the results of the 2014 search. </p> </section> <section id="CD008074-sec-0062"> <h4 class="title">Data extraction and management</h4> <section id="CD008074-sec-0063"> <h5 class="title">1. Extraction</h5> <p>For the 2014 search, review author JS extracted data from all included studies. In addition, to ensure reliability, review authors KS and SS independently extracted data from a random sample of these studies, comprising 10% of the total. We would have discussed any disagreement, documented decisions and, if necessary, contacted authors of studies. We extracted data presented only in graphs and figures whenever possible, but included only if two review authors independently had the same result. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. </p> <p>For the 2017 search, review author EGO extracted data from the new included study and re‐inspected the data extraction from previously included studies. </p> </section> <section id="CD008074-sec-0064"> <h5 class="title">2. Management</h5> </section> <section id="CD008074-sec-0065"> <h5 class="title">2.1 Forms</h5> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD008074-sec-0066"> <h5 class="title">2.2 Scale‐derived data</h5> <p>We included continuous data from rating scales only if:<br/> a) the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD008074-bbs2-0071" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b) the measuring instrument had not been written or modified by one of the trialists for that particular trial;<br/> c) the instrument should be a global assessment of an area of functioning and not sub‐scores which are not, in themselves, validated or shown to be reliable, however there are exceptions; we included sub‐scores from mental state scales measuring positive and negative symptoms of schizophrenia. </p> <p>Ideally, the measuring instrument should either be i. self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly, therefore, in <a href="#CD008074-sec-0108">Description of studies</a> we noted if this was the case or not. </p> </section> <section id="CD008074-sec-0067"> <h5 class="title">2.3 Endpoint versus change data</h5> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis and we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<a href="./references#CD008074-bbs2-0040" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD008074-sec-0068"> <h5 class="title">2.4 Skewed data</h5> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: </p> <p>a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors; </p> <p>b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<a href="./references#CD008074-bbs2-0026" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7068):1200. ">Altman 1996</a>; <a href="./references#CD008074-bbs2-0054" title="HigginsJPT , GreenS (editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>); </p> <p>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), (<a href="./references#CD008074-bbs2-0061" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>)), which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐ S min), where S is the mean score and ’S min’ is the minimum score. </p> <p>Endpoint scores on scales often have a finite start and end point and these rules can be applied. Skewed data pose less of a problem when looking at means if the sample size is large (&gt; 200) and we entered these into the syntheses. We planned to present skewed data from studies of less than 200 participants in ‘Additional tables’ rather than in analyses. </p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. These data were entered into analyses. </p> </section> <section id="CD008074-sec-0069"> <h5 class="title">2.5 Common measure</h5> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD008074-sec-0070"> <h5 class="title">2.6 Conversion of continuous to binary</h5> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD008074-bbs2-0080" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD008074-bbs2-0061" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD008074-bbs2-0067" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005</a>; <a href="./references#CD008074-bbs2-0068" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD008074-sec-0071"> <h5 class="title">2.7 Direction of graphs</h5> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for aripiprazole is effective for psychosis‐induced aggression or agitation. Where keeping to this makes it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved'), we reported data where the left of the line indicates an unfavourable outcome. This is noted in the relevant graphs. </p> </section> </section> <section id="CD008074-sec-0072"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors EGO and JS assessed risk of bias by using the criteria described in the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD008074-bbs2-0055" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.<br/> <br/> We noted the level of risk of bias in both the text of the review and in the 'Summary of findings' tables. </p> </section> <section id="CD008074-sec-0073"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008074-sec-0074"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD008074-bbs2-0034" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD008074-bbs2-0039" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial outcome/number needed to treat for an additional harmful outcome(NNTB/NNTH) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD008074-bbs2-0059" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' tables, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD008074-sec-0075"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (SMD). However, if scales of very considerable similarity had been used, we would have presumed there was a small difference in measurement, and calculated the effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD008074-sec-0076"> <h4 class="title">Unit of analysis issues</h4> <section id="CD008074-sec-0077"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD008074-bbs2-0041" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD008074-bbs2-0031" title="BlandJM , KerrySM . Trials randomised in clusters. BMJ1997;315(7108):600. ">Bland 1997</a>; <a href="./references#CD008074-bbs2-0051" title="GullifordMC , UkoumonneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>If clustering was not been accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. We would have attempted to contact the first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD008074-bbs2-0051" title="GullifordMC , UkoumonneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>If clustering had been incorporated into the analysis of primary studies, we would have reported these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>Cochrane Schizophrenia have sought statistical advice and have been advised that the binary data presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="./references#CD008074-bbs2-0042" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21(19):2971‐80. ">Donner 2002</a>). If the ICC is not reported, it is assumed to be 0.1 (<a href="./references#CD008074-bbs2-0092" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: A systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>).<br/> Where cluster studies are appropriately analysed taking into account ICCs, and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD008074-sec-0078"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD008074-bbs2-0046" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we would have only used data from the first phase of cross‐over studies. </p> </section> <section id="CD008074-sec-0079"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, where relevant, we presented the additional treatment arms in separate comparisons. If data were binary, we simply added and combined within the two‐by‐two table. If data were continuous, we combined data following the formula in section the <i>Cochrane Handbook for Systematic reviews of Interventions (</i><a href="./references#CD008074-bbs2-0054" title="HigginsJPT , GreenS (editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). If the additional treatment arms had not been relevant, we would not have reproduced such data. </p> </section> </section> <section id="CD008074-sec-0080"> <h4 class="title">Dealing with missing data</h4> <section id="CD008074-sec-0081"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD008074-bbs2-0095" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses (except for the outcome 'leaving the study early'). When more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' tables by down‐grading quality. </p> </section> <section id="CD008074-sec-0082"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis, ITT). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, we used the rate of those who stayed in the study ‐ in that particular arm of the trial ‐ for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when 'completer' data only were compared to the ITT analysis using the above assumptions. </p> </section> <section id="CD008074-sec-0083"> <h5 class="title">3. Continuous</h5> <section id="CD008074-sec-0084"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50% and 'completer'‐data were reported, we reproduced these. </p> </section> <section id="CD008074-sec-0085"> <h6 class="title">3.2 Standard deviations (SDs)</h6> <p>If SDs were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals were available for group means, and either 'P' value or 't' values were available for differences in mean, we would have calculated them according to the rules described in the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD008074-bbs2-0054" title="HigginsJPT , GreenS (editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). When only the SE are reported, SDs can be calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD008074-bbs2-0054" title="HigginsJPT , GreenS (editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulae do not apply, we could calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD008074-bbs2-0049" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We would have examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD008074-sec-0086"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or were lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently methods such as multiple imputation or mixed‐effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to somewhat better than LOCF (<a href="./references#CD008074-bbs2-0066" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups could be often the core problem in randomised schizophrenia trials. We therefore did not exclude studies based on the statistical approach used. However, preferably we used the more sophisticated approaches, e.g. we preferred MMRM or multiple‐imputation to LOCF and only presented completer analyses if some kind of ITT data were not available at all; this issue was addressed in the item 'incomplete outcome data' of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD008074-sec-0087"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD008074-sec-0088"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We inspected all studies for clearly outlying people or situations which we had not predicted would arise. If such situations or participant groups had arisen, we would have discussed them. </p> </section> <section id="CD008074-sec-0089"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We inspected all studies for clearly outlying methods which we had not predicted would arise. If such methodological outliers had arisen, we would have discussed them. </p> </section> <section id="CD008074-sec-0090"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD008074-sec-0091"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD008074-sec-0092"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> statistic alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD008074-bbs2-0053" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<sup>2</sup>  test, or a CI for I<sup>2</sup>). We interpreted an I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, as evidence of substantial levels of heterogeneity (Chapter 9. <i>Cochrane Handbook for Systematic Reviews of Interventions</i>) (<a href="./references#CD008074-bbs2-0040" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). If substantial levels of heterogeneity had been found in the primary outcome, we planned to explore reasons for heterogeneity (<a href="#CD008074-sec-0097">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD008074-sec-0093"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD008074-bbs2-0045" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13:629‐34. ">Egger 1997</a>). These are described in Chapter 10. of the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD008074-bbs2-0087" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Sterne 2011</a>). </p> <section id="CD008074-sec-0094"> <h5 class="title">1. Protocol versus full study</h5> <p>We tried to locate protocols of included randomised trials. If the protocol was available, we compared outcomes in the protocol and in the published report . If the protocol was not available, we compared outcomes listed in the methods section of the trial report with actually reported results. </p> </section> <section id="CD008074-sec-0095"> <h5 class="title">2. Funnel plot</h5> <p>We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We decided that we would not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In future, where funnel plots are possible, we will seek statistical advice in their interpretation. </p> </section> </section> <section id="CD008074-sec-0096"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose fixed‐effect model for all analyses. </p> </section> <section id="CD008074-sec-0097"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD008074-sec-0098"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD008074-sec-0099"> <h6 class="title">1.1 Primary outcomes</h6> <p>We did not anticipate any subgroup analyses.</p> </section> </section> <section id="CD008074-sec-0100"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, we reported it. First, we investigated whether data were entered correctly. Second, if data were correct, we visually inspected the graph and successfully removed outlying studies to see if homogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present such data. If not, we would not pool data, but would discuss this issue. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state.<br/> <br/> When unanticipated clinical or methodological heterogeneity were obvious, we stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD008074-sec-0101"> <h4 class="title">Sensitivity analysis</h4> <section id="CD008074-sec-0102"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the main outcomes of interest, we we would have included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have used all relevant from data these studies. </p> </section> <section id="CD008074-sec-0103"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD008074-sec-0080">Dealing with missing data</a>), we compared the findings of the main outcomes of interest when we used our assumption compared with 'completer' data only. Where there was a substantial difference, we reported results and discussed them but continued to employ our assumption.<br/> <br/> Where assumptions had to be made regarding missing SDs data (see <a href="#CD008074-sec-0080">Dealing with missing data</a>), we compared the findings of the main outcomes of interest when we used our assumption compared with 'completer' data only. We undertook a sensitivity analysis to test how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD008074-sec-0104"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (see <a href="#CD008074-sec-0093">Assessment of reporting biases</a>). If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analyses. </p> </section> <section id="CD008074-sec-0105"> <h5 class="title">4. Imputed values</h5> <p>We also would have undertaken a sensitivity analysis to assess the effects of including data from trials if we had used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> <p>If substantial differences were noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately. </p> </section> <section id="CD008074-sec-0106"> <h5 class="title">5. Fixed and random effects</h5> <p>All data were synthesised using a fixed‐effect model; however, we also synthesised data for the main outcomes using a random‐effects model to evaluate whether this altered the significance of the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008074-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008074-sec-0107"></div> <section id="CD008074-sec-0108"> <h3 class="title">Description of studies</h3> <p>For substantive descriptions of studies please see <a href="./references#CD008074-sec-0238" title="">Characteristics of included studies</a>, <a href="./references#CD008074-sec-0239" title="">Characteristics of excluded studies</a>, <a href="./references#CD008074-sec-0240" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD008074-sec-0241" title="">Characteristics of ongoing studies</a>. </p> <section id="CD008074-sec-0109"> <h4 class="title">Results of the search</h4> <p>The electronic search (December 2014) yielded 51 citations of potentially eligible studies. We obtained 51 full‐text papers, related to 17 different studies (two included studies, 13 excluded, one awaiting classification, one ongoing study, <a href="#CD008074-fig-0002">Figure 2</a>).<br/> <br/> The last search (April 2017) yielded 25 citations of potentially eligible studies, with 13 of those already cited in the previous search; therefore, we obtained and closely inspected 12 new full‐text papers related to four studies (one study included, three studies excluded, <a href="#CD008074-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008074-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram (2014 search)." data-id="CD008074-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (2014 search).</p> </div> </div> </div> <div class="figure" id="CD008074-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram (2017 search)." data-id="CD008074-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (2017 search).</p> </div> </div> </div> </section> <section id="CD008074-sec-0110"> <h4 class="title">Included studies</h4> <p>Details of the three studies included in the review are provided in the <a href="./references#CD008074-sec-0238" title="">Characteristics of included studies</a> table. </p> <section id="CD008074-sec-0111"> <h5 class="title">1. Length of studies</h5> <p>The duration of the studies, limited to intramuscular (IM) intervention phase, was up to 24 hours (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>, <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>; <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>). </p> </section> <section id="CD008074-sec-0112"> <h5 class="title">2. Participants</h5> <p>A total number of 707 patients were considered for this review; please note that for <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>, the participants reported below refer to those allocated to selected comparisons only (placebo, aripiprazole 9.75 mg, haloperidol). </p> <section id="CD008074-sec-0113"> <h6 class="title">2.1 Clinical state</h6> <p>Participants in the trials presented with acute aggression or agitation due to psychosis and therefore were deemed by the treating clinician to be appropriate candidates for IM rapid tranquillisation therapy. </p> </section> <section id="CD008074-sec-0114"> <h6 class="title">2.2 Diagnosis</h6> <p>Overall, 526 (74.4%) of participants had a diagnosis of schizophrenia, 176 (24.9%) of schizoaffective disorder, and 5 (0.7%) of schizophreniform disorder. </p> </section> <section id="CD008074-sec-0115"> <h6 class="title">2.3 Exclusion</h6> <p>Exclusion criteria in <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> and <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> studies were similar: psychoactive substance dependence within two months of the study start, significant risk of committing suicide, neurologic condition, psychiatric condition requiring pharmacotherapy other than those included, significant medical condition, known non‐responders to antipsychotic medication; PANSS (Excited Component (PEC) score ≥ 32; in <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>, schizophreniform disorder was considered an exclusion criteria, whilst in <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> it was not.<a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>, a more pragmatic randomised controlled trial (RCT), had less restrictive exclusion criteria: known allergy to aripiprazole or olanzapine, pregnancy or breastfeeding. </p> </section> <section id="CD008074-sec-0116"> <h6 class="title">2.4 Age</h6> <p>Age range was of 18‐69 years in <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>, 18‐66 years in <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>, and 18‐65 years in <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>. </p> </section> <section id="CD008074-sec-0117"> <h6 class="title">2.5 Sex</h6> <p>Participants of the studies involved in this review were 435 men (61.5%) and 272 women (38.5%). </p> </section> </section> <section id="CD008074-sec-0118"> <h5 class="title">3. Study size</h5> <p>The total number of participants randomised was 805 (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>, n = 448; <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>, n = 357, of which 179 were considered for comparisons; <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>, n = 80). </p> </section> <section id="CD008074-sec-0119"> <h5 class="title">4. Setting</h5> <p>All the included studies were located in emergency room departments and subsequently in hospital, involving newly admitted patients. </p> </section> <section id="CD008074-sec-0120"> <h5 class="title">5. Interventions</h5> <section id="CD008074-sec-0121"> <h6 class="title">5.1 Aripiprazole IM</h6> <p>Data in this systematic review relate to the 9.75 mg dose of aripiprazole for all the studies (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>; <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>; <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>). </p> </section> <section id="CD008074-sec-0122"> <h6 class="title">5.2 Placebo IM</h6> <p>Both <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> and <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> used placebo given intramuscularly. </p> </section> <section id="CD008074-sec-0123"> <h6 class="title">5.3 Haloperidol IM</h6> <p>Dosage varied from 6.5 mg (<a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>) to 7.5 mg (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>). </p> </section> <section id="CD008074-sec-0124"> <h6 class="title">5.4 Olanzapine IM</h6> <p>Dosage was 10 mg (<a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>). </p> </section> </section> <section id="CD008074-sec-0125"> <h5 class="title">6. Outcomes</h5> <p>Binary data concerning the repeated need for tranquillisation were available for <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> and <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> only, since in <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a> repeated administration of intervention drugs was prohibited by the methodological design; with respect to adverse effects, binary data were available for all the included trials. All the trials employed continuous scales to measure other clinical outcomes; in <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> and <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> continuous measurements for adverse effects were presented as means without standard deviations (SDs), standard error (SE) or confidence intervals (CIs), and therefore were unusable for quantitative analyses. The various rating scales, from which we were able to obtain usable data, are listed below: </p> <section id="CD008074-sec-0126"> <h6 class="title">6.1 Specific behaviour ‐ Agitation</h6> <section id="CD008074-sec-0127"> <p><b>a. Agitated Behavior Scale (ABS/CABS)</b></p> <p>The ABS (<a href="./references#CD008074-bbs2-0036" title="CorriganJD . Development of a scale for assessment of agitation following traumatic brain injury. Journal of Clinical and Experimental Neuropsychology1989;11(2):261‐77. ">Corrigan 1989</a>), is a 14‐item scale used for measuring agitation levels. The ABS was originally designed to monitor agitated behaviour in the recovery period after stroke and there are three factor‐based sub scores: I. aggression; II. disinhibition; III. lability. High scores indicated higher levels of aggression. </p> </section> <section id="CD008074-sec-0128"> <p><b>b. Agitation calmness Evaluation scale (ACES)</b></p> <p>The ACES (<a href="./references#CD008074-bbs2-0035" title="BreierA , MeehanK , BirkettM , DavidS , FerchlandI , SuttonV , et al. A double‐blind, placebo‐controlled dose‐response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry2002;59(5):441‐8. ">Breier 2001</a>), is a single‐item rating scale developed by Eli Lilly and company. On this scale, 1 = 'marked agitation', 4 = 'normal', 9 = 'unable to be aroused'. </p> </section> <section id="CD008074-sec-0129"> <p><b>c. Positive and Negative Syndrome Scale ‐ Excited Component (PANSS‐EC)</b></p> <p>The PANSS‐EC (<a href="./references#CD008074-bbs2-0075" title="MontoyaA , ValladaresA , LizánL , SanL , EscobarR , PazS . Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS‐EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Quality Life Outcomes2011;9:18. ">Montoya 2011</a>) is a five‐item subscale of the PANSS scale (excitement, tension, hostility, uncooperativeness, and poor impulse control). As in the original scale, items are rated from one ('not present') to seven ('extremely severe'). Scores range from five to 35, with mean scores ≥ 20 indicating agitation. A high score indicates high levels of agitation. </p> </section> </section> <section id="CD008074-sec-0130"> <h6 class="title">6.2 Global state</h6> <section id="CD008074-sec-0131"> <p><b>a. Clinical Global Impression (CGI)</b></p> <p>The CGl (<a href="./references#CD008074-bbs2-0052" title="GuyW . Clinical Global Impression. The ECDEU Assessment Manual for Psychopharmacology‐Revised, National Institute of Mental Health1976:217–21. ">Guy 1976</a>) is not a diagnostic tool but rather, enables clinicians to quantify the severity of symptoms of any mental health problem at one point in time. Clinicians are then able to use this to track whether there has been any improvement or worsening of symptoms over time. A seven‐point rating scale is used with high scores indicating increased severity or less recovery. </p> </section> <section id="CD008074-sec-0132"> <p><b>b. Clinical Global Impression ‐ Severity (CGI‐S)</b></p> <p>The CGI‐S (<a href="./references#CD008074-bbs2-0052" title="GuyW . Clinical Global Impression. The ECDEU Assessment Manual for Psychopharmacology‐Revised, National Institute of Mental Health1976:217–21. ">Guy 1976</a>) requires clinicians to consider the severity of a person’s symptoms in relation to the clinicians past experience of people with the same diagnosis. Clinicians then have to give a rating from one (= 'normal') to seven (= 'extremely ill'). High scores indicate increased severity. </p> </section> <section id="CD008074-sec-0133"> <p><b>c. Clinical Global Impression ‐ Improvement (CGI‐I)</b></p> <p>The CGI‐I (<a href="./references#CD008074-bbs2-0052" title="GuyW . Clinical Global Impression. The ECDEU Assessment Manual for Psychopharmacology‐Revised, National Institute of Mental Health1976:217–21. ">Guy 1976</a>) enables clinicians to assess whether a person’s symptoms have improved or worsened following an intervention. Based on the clinicians judgement, a rating on a seven‐point scale is given from one (= 'very much improved') to seven (= 'very much worse'). Therefore, low scores indicate greater improvement. </p> </section> </section> <section id="CD008074-sec-0134"> <h6 class="title">6.3 Mental state</h6> <section id="CD008074-sec-0135"> <p><b>a. Brief Psychiatric Rating Scale (BPRS)</b></p> <p>The Brief Psychiatric Rating Scale was originally developed by Overall and Gorham (<a href="./references#CD008074-bbs2-0080" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) as a 14‐item scale to measure the severity of a range of psychiatric symptoms, including psychosis. This rating scale items evolved over time and now consists of 24 items which can be rated on a seven‐point scale from ‘not present’ to ‘extremely severe’. A high score would suggest poor mental health. It is not clear for the majority of the studies included in this review, which version of the BPRS was used. </p> </section> <section id="CD008074-sec-0136"> <p><b>b. Positive and Negative Syndrome Scale (PANSS)</b></p> <p>The PANSS was developed and published by Kay, Flszbein and Opler (<a href="./references#CD008074-bbs2-0062" title="KaySR , FiszbeinA , OpferLA . The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin1987;13(2):261–76. ">Kay 1987</a>). The PANSS is designed as a brief interview, whereby the severity of 30 symptoms of schizophrenia can be assessed on a scale of one ('not present') to seven ('extremely severe'). A high score would indicate more severe symptoms. The PANSS can be divided into separate subscales by focusing on the statements relating to positive symptoms (e.g. hallucinations), negative symptoms (e.g. social withdrawal) or general psychopathology (e.g. anxiety and uncooperativeness). </p> </section> </section> <section id="CD008074-sec-0137"> <h6 class="title">6.4 Adverse effects</h6> <section id="CD008074-sec-0138"> <p><b>a. Udvalg for Kliniske Undersogelser (UKU) side effects rating scale</b></p> <p>The UKU (<a href="./references#CD008074-bbs2-0069" title="LingjaerdeO , AhlforsUG , BechP , DenckerSJ , ElgenK . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychiatrica Scandinavica. Supplementum1987;334:1‐100. ">Lingjaerde 1987</a>) is a questionnaire that divides adverse effects into four general categories of symptoms: psychic, neurologic, autonomic, and miscellaneous; for each adverse effects, the interviewer is asked to assess the probability of causal relationship with psychotropic drugs. </p> </section> <section id="CD008074-sec-0139"> <p><b>b. Simpson‐Angus Scale (SAS)</b></p> <p>The SAS (<a href="./references#CD008074-bbs2-0086" title="SimpsonGM , AngusJSW . A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum1970;212:11‐9. ">Simpson 1970</a>) is a 10‐item scale which measures drug‐induced parkinsonism (extrapyramidal side effects). Each item is scored from zero to four. A high score would indicate increased levels of parkinsonism. </p> </section> </section> </section> <section id="CD008074-sec-0140"> <h5 class="title">7. Missing outcomes</h5> <p>No studies evaluated satisfaction with care, acceptance of treatment, quality of life, or economic outcomes. </p> </section> <section id="CD008074-sec-0141"> <h5 class="title">8. Funders</h5> <p><a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> and <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> studies received sponsorship from pharmaceutical companies. </p> </section> </section> <section id="CD008074-sec-0142"> <h4 class="title">Excluded studies</h4> <p>In total we excluded 16 studies. Of these, seven had to be excluded based on the characteristics of participants. These studies (<a href="./references#CD008074-bbs2-0008" title="AnutoshS , AliMW , IngenitoG , CarsonWH . Controlled study of aripiprazole and haloperidol in schizophrenia. European Psychiatry2002;17(Suppl 1):103s. CarsonWH , AliM , SahaAR , DunbarGC , IngenitoG . A double‐blind, placebo‐controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. [XXIIND: C.I.N.P. [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000] KaneJM , CarsonWH , SahaAR , McQuadeRD , IngenitoGG , ZimbroffDL , et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry2002;63(9):763‐71. [2002343924] KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. [153RD: Annual Meeting of the American Psychiatric Association [CD‐ROM]: MARATHON Multimedia, 2000] KaneJM , IngenitoG , AliM . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. ">Kane 2002</a>; <a href="./references#CD008074-bbs2-0006" title="CutlerAJ , MarcusRN , HardySA , O'DonnellA , CarsonWH , McQuadeRD . The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectrums2006;11(9):691‐702. [EMBASE: 2006471567; MEDLINE: 0; MEDLINE: 16946694] ">Cutler 2006</a>; <a href="./references#CD008074-bbs2-0007" title="FleischhackerWW , McQuadeRD , MarcusRN , ArchibaldD , SwaninkR , CarsonWH . A double‐blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biological Psychiatry2009;65(6):510‐7. [MEDLINE: 18986646] ">Fleischhacker 2009</a>; <a href="./references#CD008074-bbs2-0011" title="LiangS . A multi‐center, randomized, double‐blind study, comparing with risperidone, to evaluate the efficacy and safety of aripiprazole in the treatment of patients with schizophrenia. http:,www.clinicaltrials.gov2005. ">Liang 2005</a>; <a href="./references#CD008074-bbs2-0013" title="McEvoyJP , DanielDG , CarsonWHJr , McQuadeRD , MarcusRN . A randomized, double‐blind, placebo‐controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. Journal of Psychiatric Research2007;41(11):895‐905. [EMBASE: 2007402756; MEDLINE: 0; MEDLINE: 17631314; PsycINFO] ">McEvoy 2007</a>; <a href="./references#CD008074-bbs2-0015" title="CarsonWH , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [11TH: Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001] CarsonWHJ , SahaAR , AliM , DunbarGC , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60:300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. [EMBASE: 2003275542; MEDLINE: 12860772] SahaA , CarsonW , AliM , DunbarG , IngenitoG . Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. 7th World Congress of Biological Psychiatry; 2001 Jul 1‐6; Berlin, Germany. 2001; Vol. 2, issue Suppl 1. [7TH: World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001] YeungP , KujawaM , CarsonWH , SahaA , AlidM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2002;53(3 Suppl 1):185‐6. [11TH: Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001] YeungP , McQuadeRD , CarsonWH , SahaA , AliMW , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry2002;17(Suppl 1):102s. ">Potkin 2003</a>; <a href="./references#CD008074-bbs2-0017" title="TandonR , MarcusRN , StockEG , RieraLC , KosticD , PansM , et al. A prospective, multicenter, randomized, parallel‐group, open‐label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia Research2006;84(1):77‐89. [EMBASE: 2006399870; MEDLINE: 0; MEDLINE: 16483745] ">Tandon 2006</a>) were excluded because although participants were suspected to have psychosis, these people were not displaying an aggressive or agitated behaviour. Five studies had to be excluded because they involved oral administration of aripiprazole (<a href="./references#CD008074-bbs2-0005" title="陈远岭 , 黄文武 , 叶鑫武 . Aripiprazole treatment of agitation associated with schizophrenia] Google Translate [阿立哌唑治疗伴激越的精神分裂症对照研究 []. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(4):261‐2. ">Chen 2009</a>; <a href="./references#CD008074-bbs2-0009" title="EliLilly , Company . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry2004. KinonBJ , StaufferVL , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(6):601‐7. [MEDLINE: 19011427] NCT00103571 . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. http://www.clinicaltrials.gov2005. StaufferV , KinonB , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8, Washington DC, USA. 2008. [NR4‐109] ">Kinon 2008</a>; <a href="./references#CD008074-bbs2-0010" title="李树生 . Aripiprazole for schizophrenia combined magnesium valproate efficacy of impulse control disorders] Google Translate [阿立哌唑联合丙戊酸镁对精神分裂症冲动控制障碍的疗效观察]. Chongqing Medical Journal2009;38(7):788‐9. ">Li 2009</a>; <a href="./references#CD008074-bbs2-0012" title="刘杰 . 丙戊酸镁对精神分裂症兴奋激越行为的辅助疗效观察. 社区医学杂志2012;10(14):31‐2. ">Liu 2012</a>; <a href="./references#CD008074-bbs2-0019" title="颉瑞 , 王刚平 , 裴根祥 . Clinical observation of magnesium valproate sustained release tablets adjuvant treatment of schizophrenia attacks [丙戊酸镁缓释片辅助治疗精神分裂症攻击行为的疗效观察]. 临床精神医学杂志2011;21(03):191‐2. ">Xie 2011</a>) or the intramuscular administration of aripiprazole long acting (<a href="./references#CD008074-bbs2-0014" title="CitromeL , DuY , RisingerR , StankovicS , ClaxtonA , ZummoJ , et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology2016;31(2):69‐75. CitromeL , DuY , RisingerR , StankovicS , ClaxtonA , ZummoJ , et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia: Erratum. International Clinical Psychopharmacology2017;32(1):56. HardM , StankovicS , RisingerR , BoseA , DuY , ZummoJ , et al. Efficacy of aripiprazole lauroxil, a new long‐acting injectable atypical antipsychotic, across three geographic regions. Neuropsychopharmacology2014;39:S359‐60. MeltzerHY , NasrallahHA , RisingerR , DuY , ZummoJ , CoreyL , et al. Aripiprazole lauroxil: an innovative long‐acting injectable in development for treatment of schizophrenia. 168th Annual Meeting of American Psychiatric Association; Toronto, Canada; May 16‐20, 2015. 2015. MeltzerHY , RisingerR , NasrallahHA , DuY , ZummoJ , CoreyL , et al. A randomized, double‐blind, placebo‐controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. Journal of Clinical Psychiatry2015;76(8):1085‐90. NCT01469039 . A study to evaluate the efficacy and safety of alks 9072 (also known as alks 9070) in subjects with schizophrenia. http://ClinicalTrials.gov/show/NCT014690392011. NasrallahHA , NewcomerJW , RisingerR , DuY , ZummoJ , BoseA , et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. Journal of Clinical Psychiatry2016;77(11):1519‐25. TargumSD , RisingerR , DuY , PendergrassJC , JamalHH , SilvermanBL . Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia [2017 Jan;179:64‐69.]. Schizophrenia Research2017;179:64‐9. ">NCT01469039</a>). Three studies (<a href="./references#CD008074-bbs2-0004" title="BaoL‐Y , WangK‐M . The effectiveness of aripirazole combined with clonazepam treated with agitation in schizophrenia. Medical Journal of Chinese People's Health2007;19(3):198‐200. [CHINESE: Academic Journals] ">Bao 2007</a>; <a href="./references#CD008074-bbs2-0016" title="SimpsonG , MohammadAR , FauziaS , CampaneauM , LaskaE , NinahR , et al. A comparison of rapid titration quetiapine and haloperidol in agitated adults in an emergency setting. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. ">Simpson 2010</a>; <a href="./references#CD008074-bbs2-0018" title="王琦 , 周丹 , 李萍 , 谢红涛 . 非典型抗精神病药对精神分裂症患者激越行为的随机对照研究. 中国健康心理学杂志2014;22(3):325‐7. ">Wang 2014</a>) had to be excluded because the intervention medication was not aripiprazole alone. </p> </section> </section> <section id="CD008074-sec-0143"> <h3 class="title">Risk of bias in included studies</h3> <p>Although each ’Summary of findings’ table describes bias by outcome, an overview is reported here and a graphical impression is seen in <a href="#CD008074-fig-0004">Figure 4</a> and in <a href="#CD008074-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD008074-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008074-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD008074-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008074-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD008074-sec-0144"> <h4 class="title">Allocation</h4> <p>All included studies were described as randomised. In <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>, the randomisation process is not stated (unclear sequence generation risk); however, allocation concealment was preserved by the utilisation of a centralised call‐in system (low allocation concealment risk). In <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> patients were randomly assigned in 1:1:1:1:1:1 ratio to the six arms of the study but no further information was provided regarding the process of randomisation; no details were provided regarding allocation concealment (overall unclear risk of selection bias). In <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>, the randomisation process is low risk as it is described as blindly picking the name of the assigned medication from a box with equal numbers of folded papers printed with each medication; allocation concealment management is not stated (unclear risk ). </p> </section> <section id="CD008074-sec-0145"> <h4 class="title">Blinding</h4> <p><a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> is described as a double‐blinded study but no further details are provided (unclear risk of performance bias; unclear risk of detection bias). In the <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> study, authors stated double‐blinding but different dilution instructions for drug injections were provided, so no blinding was possible during the preparation of injections; in most cases the same person prepared and administered the drug (high risk of performance bias). To limit the magnitude of this bias, in the efficacy evaluations study investigators were blinded to treatment (low risk of detection bias), giving an overall unclear risk for blinding. In one case of medical emergency, the treating physician broke the blind design as knowledge of investigational product was considered to be critical to the patient management; however, investigators remained blinded. In <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>, patients and the physician investigator were blinded to treatment assignment. </p> </section> <section id="CD008074-sec-0146"> <h4 class="title">Incomplete outcome data</h4> <p>Two included studies used a 'Last Observation Carried Forward' (LOCF) approach to manage missing data. In <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>, there was no evidence of attrition bias (low risk of attrition bias). Concerning <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>, reasons for leaving the study early were reported; however, number of participants completing different assessments at the same time point vary and reasons are not given (unclear risk of attrition bias). In <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>, procedures to manage missing data are not reported in the method section but no attritions were recorded throughout the trial (low risk of attrition bias). </p> </section> <section id="CD008074-sec-0147"> <h4 class="title">Selective reporting</h4> <p>In both <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> and <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>, adverse effects were reported only if they occurred in ≥ 5% of participants (high risk of reporting bias). In <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>, there was no evidence of reporting bias. </p> </section> <section id="CD008074-sec-0148"> <h4 class="title">Other potential sources of bias</h4> <p>Both <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> and <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> were supported by manufacturers of one of the compared drugs (high risk of other bias). <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a> had no obvious risk of other bias. </p> </section> </section> <section id="CD008074-sec-0149"> <h3 class="title" id="CD008074-sec-0149">Effects of interventions</h3> <p>See: <a href="./full#CD008074-tbl-0001"><b>Summary of findings for the main comparison</b> ARIPIPRAZOLE (IM) compared to PLACEBO/NIL for psychosis‐induced aggression or agitation (rapid tranquillisation)</a>; <a href="./full#CD008074-tbl-0002"><b>Summary of findings 2</b> ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: a. HALOPERIDOL for psychosis‐induced aggression or agitation (rapid tranquillisation)</a>; <a href="./full#CD008074-tbl-0003"><b>Summary of findings 3</b> ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE for psychosis‐induced aggression or agitation (rapid tranquillisation)</a> </p> <p>See <a href="./full#CD008074-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD008074-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008074-tbl-0003">summary of findings Table 3</a>.<br/> In the following section, the summary statistic for binary outcome results is reported as risk ratio (RR), and for continuous outcomes we used mean difference (MD). In all instances 95% confidence intervals (CIs) are reported. </p> <section id="CD008074-sec-0150"> <h4 class="title">1. COMPARISON 1. ARIPIPRAZOLE (intramuscular) versus PLACEBO/NIL</h4> <section id="CD008074-sec-0151"> <h5 class="title">1.1 Repeated need for tranquillisation</h5> <p>Overall, significantly fewer participants allocated to aripiprazole needed additional injections during 24 hours, when compared to placebo (2 RCTs, n = 382, RR 0.69, 95% CI 0.56 to 0.85, <i>very low‐quality evidence</i>). Analyses for numbers needing one additional injection showed no differences between groups (1 RCT, n = 119, RR 1.38, 95% CI 0.69 to 2.80) but significantly more people receiving placebo required two additional injections (1 RCT, n = 119, RR 0.36, 95% CI 0.19 to 0.70, <a href="./references#CD008074-fig-0006" title="">Analysis 1.1</a>). </p> </section> <section id="CD008074-sec-0152"> <h5 class="title">1.2 Specific behaviour ‐ agitation</h5> <section id="CD008074-sec-0153"> <h6 class="title">1.2.1 Clinically important change</h6> <p>Aripiprazole had an effect on agitation. At two hours more participants in the aripiprazole group showed a positive response for agitation (defined as a PANSS ‐ EC reduction of ≥ 40% from baseline, 2 RCTs, n = 382, RR 1.50. 95% CI 1.17 to 1.92, <i>very low‐quality evidence</i><a href="./references#CD008074-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD008074-sec-0154"> <h6 class="title">1.2.2 Average scores</h6> <p>Continuous measures of agitation (up to two hours) also favoured aripiprazole: ABS change score (2 RCTs, n = 380, MD ‐3.77, 95% CI ‐5.39 to ‐2.16), ACES change score (2 RCTs, n = 380, MD ‐0.71, 95% CI ‐1.15 to ‐0.28) and PANSS‐EC change score (1 RCT, n = 261, MD ‐2.49, 95% CI ‐4.28 to ‐0.70).<br/> <br/> These findings were still favourable for aripiprazole for both a schizophrenia subgroup (2 RCTs, n = 263, MD ‐2.55, 95% CI ‐3.78 to ‐1.32), and a non‐sedated participants subgroup ‐ based on ACES score (2 RCTs, n = 355, MD ‐2.68, 95% CI ‐3.75 to ‐1.62) and on AEs (2 RCTs, n = 365, MD ‐2.83, 95% CI ‐3.92 to ‐1.75, <a href="./references#CD008074-fig-0008" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD008074-sec-0155"> <h5 class="title">1.3 Global state</h5> <section id="CD008074-sec-0156"> <h6 class="title">Various</h6> <p>There were fewer non‐responders at first injection in aripiprazole group (1 RCT, n = 263, RR 0.49, 95% CI 0.34 to 0.71,<i>low‐quality evidence</i>) and participants allocated to aripiprazole had a significantly lower need for additional intervention with benzodiazepines (2 RCTs, n = 382, RR 0.48, 95% CI 0.28 to 0.80, <a href="./references#CD008074-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD008074-sec-0157"> <h6 class="title">1.3.2 Average scores ‐ up to two hours</h6> <p>Rating scales showed a significant advantage for participants allocated to aripiprazole: CGI‐I endpoint score (2 RCTs, n = 380, MD ‐0.73, 95% CI ‐0.97 to ‐0.49), CGI‐S change score (2 RCTs, n = 380, MD ‐0.56, 95% CI ‐0.86 to ‐0.26). CGI‐I endpoint score was also lower in the aripiprazole group for participants with a schizophrenia diagnosis (1 RCT, n = 75, MD ‐0.71, 95% CI ‐1.17 to ‐0.25, <a href="./references#CD008074-fig-0010" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD008074-sec-0158"> <h5 class="title">1.4 Mental state ‐ average scores ‐ up to two hours</h5> <p>Change score of PANSS‐derived BPRS total (1 RCT, n = 110, MD ‐3.39, 95% CI ‐7.03 to 0.25) and positive subscale (1 RCT, n = 110, MD ‐0.62, 95% CI ‐1.65 to 0.41) were similar between aripiprazole and placebo groups (<a href="./references#CD008074-fig-0011" title="">Analysis 1.6</a>). </p> </section> <section id="CD008074-sec-0159"> <h5 class="title">1.5 Adverse effects</h5> <section id="CD008074-sec-0160"> <h6 class="title">1.5.1 General</h6> <p>More participants allocated to aripiprazole experienced one or more drug‐related adverse effects by two hours (1 RCT, n = 117, RR 1.51, 95% CI 0.93 to 2.46, <i>very low‐quality evidence</i>), and onset or worsening of adverse effects following the second injection (1 RCT, n = 262, RR 2.40, 95% CI 1.36 to 4.23, <a href="./references#CD008074-fig-0012" title="">Analysis 1.7</a>). </p> <p>Similar findings were found for serious adverse effects, which were higher in the aripiprazole group when compared to placebo group (2 RCTs, n = 379, RR 3.77, 95% CI 0.63 to 22.60); in the aripiprazole group a tonic clonic seizure event occurred (1 RCT, n = 117, RR 3.26, 95% CI 0.14 to 78.49, <a href="./references#CD008074-fig-0013" title="">Analysis 1.8</a>). No deaths were reported. </p> </section> <section id="CD008074-sec-0161"> <h6 class="title">1.5.2 Specific ‐ arousal</h6> <p>No clear effect was found for other effects such as 'insomnia during 24 hours' (1 RCT, n = 262, RR 0.62, 95% CI 0.25 to 1.52), 'over'‐sedated (1 RCT, n = 262, RR 1.59, 95% CI 0.60 to 4.20) somnolence (2 RCTs, n = 379, RR 1.52, 95% CI 0.57 to 4.00, <a href="./references#CD008074-fig-0014" title="">Analysis 1.9</a>). </p> </section> <section id="CD008074-sec-0162"> <h6 class="title">1.5.3 Specific ‐ cardiovascular</h6> <p>Again, similar numbers in each treatment group experienced dizziness (2 RCTs, n = 379, RR 1.77, 95% CI 0.66 to 4.70), tachycardia (1 RCT, n = 117, RR 4.36, 95% CI 0.50 to 37.82) during 24 hours and sinus tachycardia (1 RCT, n = 117, RR 0.36, 95% CI 0.02 to 8.72, <a href="./references#CD008074-fig-0015" title="">Analysis 1.10</a>). </p> </section> <section id="CD008074-sec-0163"> <h6 class="title">1.5.4 Specific ‐ movement disorders</h6> <p>Drug‐related adverse effects were experienced only by participants allocated to aripiprazole during 24 hours but no effect between treatment groups was observed for akathisia (1 RCT, n = 117, RR 7.61, 95% CI 0.40 to 144.21), dystonia (1 RCT, n = 117, RR 3.26, 95% CI 0.14 to 78.49) and extrapyramidal symptoms (1 RCT, n = 262, RR 1.50 95% CI 0.06 to 36.45, <a href="./references#CD008074-fig-0016" title="">Analysis 1.11</a>). </p> </section> <section id="CD008074-sec-0164"> <h6 class="title">1.5.5 Miscellaneous</h6> <p>More participants allocated to the aripiprazole group experienced nausea during 24 hours (2 RCTs, n = 379, RR 3.97 95% CI 1.13 to 13.92).<br/> Concerning other miscellaneous adverse effects, no observable differences were found: agitation (2 RCTs, n = 379, RR 0.88 95% CI 0.33 to 2.37), headache (2 RCTs, n = 379, RR 1.66 95% CI 0.74 to 3.71), pain at injection site (2 RCTs, n = 379, RR 1.10 95% CI 0.30 to 3.94), and vomiting (1 RCT, n = 117, RR 2.18 95% CI 0.20 to 23.37, <a href="./references#CD008074-fig-0017" title="">Analysis 1.12</a>). </p> </section> </section> <section id="CD008074-sec-0165"> <h5 class="title">1.6 Leaving the study early</h5> <p>We found no clear difference for numbers of participants leaving the study early for 'any reason' (2 RCTs, n = 382, RR 1.29, 95% CI 0.35 to 4.74); 'lack of efficacy' (2 RCTs, n = 382, RR 0.47, 95% CI 0.07 to 3.06), 'consent withdrawal' (2 RCTs, n = 382, RR 1.68, 95% CI 0.23 to 12.46), 'adverse effects' (2 RCTs, n = 382, RR 2.25, 95% CI 0.25 to 20.54), and 'other' reasons (2 RCTs, n = 382, RR 1.05, 95% CI 0.15 to 7.44, <a href="./references#CD008074-fig-0018" title="">Analysis 1.13</a>). </p> </section> </section> <section id="CD008074-sec-0166"> <h4 class="title">2. COMPARISON 2. ARIPIPRAZOLE (intramuscular) versus OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular) </h4> <section id="CD008074-sec-0167"> <h5 class="title">2.1 Repeated need for tranquillisation</h5> <p>Compared to haloperidol, more participants allocated to aripiprazole needed additional injections during 24 hours (2 RCTs, n = 477, RR 1.28, 95% CI 1.00 to 1.63, <i>very low‐quality evidence</i>). A comparable pattern was found in terms of need of 1 additional injection (1 RCT, n = 117, RR 1.34, 95% CI 0.66 to 2.70) and 2 additional injections (1 RCT, n = 117, RR 2.37, 95% CI 0.77 to 7.26) during 24 hours (<a href="./references#CD008074-fig-0019" title="">Analysis 2.1</a>). Even though not being statistically significant, leading to an equal to higher number of additional injections needed must be taken into account when considering clinical significance. </p> </section> <section id="CD008074-sec-0168"> <h5 class="title">2.2 Specific behaviour ‐ agitation</h5> <section id="CD008074-sec-0169"> <h6 class="title">2.2.1 Clinically important change</h6> <p>Clinically important change in agitation by two hours (defined as a PANSS‐EC reduction of ≥ 40% from baseline) was similar between groups (2 RCTs, n = 477, RR 0.94, 95% CI 0.80 to 1.11, <i>very low‐quality evidence;</i><a href="./references#CD008074-fig-0020" title="">Analysis 2.2</a>). </p> </section> <section id="CD008074-sec-0170"> <h6 class="title">2.2.2 Average scores ‐ up to two hours</h6> <p>Continuous measures of agitation showed similar findings, with no observable differences in ABS change score (2 RCTs, n = 473, MD 0.55, 95% CI ‐1.00 to 2.10), ACES change score (2 RCTs, n = 473, MD 0.12, 95% CI ‐0.30 to 0.55) and PANSS‐EC change score in the total sample (1 RCT, n = 357, MD 0.48, 95% CI ‐1.16 to 2.12), nor in schizophrenia subgroup (2 RCTs, n = 336, MD 0.07, 95% CI ‐0.99 to 1.13), or non‐sedated patients (based on ACES score: 2 RCTs, n = 422, MD 0.12, 95% CI ‐0.82 to 1.06). Based on AEs: 2 RCTs, n = 448, MD 0.26, 95% CI ‐0.68 to 1.19, <a href="./references#CD008074-fig-0021" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD008074-sec-0171"> <h5 class="title">2.3 Global state</h5> <p>Similar numbers of participants were 'non‐responders to the first injection (1 RCT, n = 360, RR 1.18, 95% CI 0.78 to 1.79, <i>low‐quality evidence</i>) and similar numbers needed benzodiazepine up to 24 hours (2 RCTs, n = 477, RR 0.79, 95% CI 0.46 to 1.35, <a href="./references#CD008074-fig-0022" title="">Analysis 2.4</a>). </p> <p>No differences between aripiprazole and haloperidol were observed for global state (as measured by CGI scale): CGI‐I endpoint score for total sample (2 RCTs, n = 473, MD 0.02, 95% CI ‐0.19 to 0.23) and in the schizophrenia subgroup (1 RCT, n = 79, MD 0.02, 95% CI ‐0.44 to 0.48), and CGI‐S change score (2 RCTs, n = 473, MD ‐0.07, 95% CI ‐0.36 to 0.22, <a href="./references#CD008074-fig-0023" title="">Analysis 2.5</a>). </p> </section> <section id="CD008074-sec-0172"> <h5 class="title">2.4 Mental state</h5> <p>Participants in aripiprazole and haloperidol groups also had similar scores on mental state scales: PANSS‐derived BPRS change score (1 RCT, n = 102, MD 2.03, 95% CI ‐1.70 to 5.76) and in the positive subscale (1 RCT, n = 103, MD 0.23, 95% CI ‐0.82 to 1.28) by two hours (<a href="./references#CD008074-fig-0024" title="">Analysis 2.6</a>). </p> </section> <section id="CD008074-sec-0173"> <h5 class="title">2.5 Adverse effects</h5> <section id="CD008074-sec-0174"> <h6 class="title">2.5.1 General</h6> <p>The same proportion of participants of aripiprazole and haloperidol group experienced one or more drug‐related adverse effects during 24 hours (1 RCT, n = 113, RR 0.91, 95% CI 0.61 to 1.35, <i>very low‐quality evidence</i>); however, more people allocated to haloperidol experienced onset or worsening of adverse effects after the second injection (1 RCT, n = 358, RR 0.74, 95% CI 0.57 to 0.96, <a href="./references#CD008074-fig-0025" title="">Analysis 2.7</a>). </p> <p>More adverse effects rated as serious were recorded in the aripiprazole group but this was not an observable difference between the treatments (2 RCTs, n = 471, RR 1.73, 95% CI 0.54 to 5.52), as was 'event of tonic clonic seizure' (1 RCT, n = 113, RR 3.05, 95% CI 0.13 to 73.38). No death events were recorded (<a href="./references#CD008074-fig-0026" title="">Analysis 2.8</a>). </p> </section> <section id="CD008074-sec-0175"> <h6 class="title">2.5.2 Specific ‐ arousal</h6> <p>More people allocated to haloperidol experienced insomnia during 24 hours (1 RCT, n = 358, RR 0.48, 95% CI 0.23 to 0.97) and, were 'over'‐sedated (1 RCT, n = 358, RR 0.60, 95% CI 0.34 to 1.07); no differences in terms of somnolence were found between aripiprazole and haloperidol groups (2 RCTs, n = 471, RR 0.81, 95% CI 0.41 to 1.58, <a href="./references#CD008074-fig-0027" title="">Analysis 2.9</a>). </p> </section> <section id="CD008074-sec-0176"> <h6 class="title">2.5.3 Specific ‐ cardiovascular</h6> <p>No real differences were found as regards the number of participants experiencing dizziness (2 RCTs, n = 471, RR 1.41, 95% CI 0.66 to 3.01) and tachycardia (1 RCT, n = 113, RR 4.07, 95% CI 0.47 to 35.31); three events of sinus tachycardia were recorded in the haloperidol group but again, no effect found (1 RCT, n = 113, RR 0.15, 95% CI 0.01 to 2.75, <a href="./references#CD008074-fig-0028" title="">Analysis 2.10</a>). </p> </section> <section id="CD008074-sec-0177"> <h6 class="title">2.5.4 Specific ‐ movement disorders</h6> <p>Significantly more participants allocated to haloperidol experienced extrapyramidal symptoms (2 RCTs, n = 471, RR 0.29, 95% CI 0.12 to 0.70, <i>very low‐quality evidence</i>); but this effect was not observed for akathisia (1 RCT, n = 113, RR 0.51, 95% CI 0.13 to 1.94) and dystonia (1 RCT, n = 113, RR 0.25, 95% CI 0.03 to 2.21), although more events were recorded in the haloperidol group (<a href="./references#CD008074-fig-0029" title="">Analysis 2.11</a>). </p> </section> <section id="CD008074-sec-0178"> <h6 class="title">2.5.5 Miscellaneous</h6> <p>A favourable effect for haloperidol was found in terms of number of participants experiencing nausea (2 RCTs, n = 471, RR 5.52, 95% CI 1.63 to 18.70). No effect was found for 'pain at injection site' (2 RCTs, n = 471, RR 3.12, 95% CI 0.75 to 12.91), agitation (2 RCTs, n = 471, RR 1.04 95% CI 0.42 to 2.58), headache (2 RCTs, n = 471, RR 1.16 95% CI 0.62 to 2.18), or vomiting during 24 hours (1 RCT, n = 113, RR 2.04 95% CI 0.19 to 21.82, <a href="./references#CD008074-fig-0030" title="">Analysis 2.12</a>). </p> </section> </section> <section id="CD008074-sec-0179"> <h5 class="title">2.6 Leaving the study early</h5> <p>No differences in numbers leaving the study early were observed between aripiprazole and haloperidol groups for either any reason (2 RCTs, n = 477, RR 0.49 95% CI 0.20 to 1.18), consent withdrawal (2 RCTs, n = 477, RR 0.35 95% CI 0.10 to 1.28), lack of efficacy (2 RCTs, n = 477, RR 1.05, 95% CI 0.15 to 7.43), adverse effects: 2 RCTs, n = 477, RR 1.06, 95% CI 0.18 to 6.04 or other reason (2 RCTs, n = 477, RR 0.75, 95% CI 0.15 to 3.78, <a href="./references#CD008074-fig-0031" title="">Analysis 2.13</a>). </p> </section> </section> <section id="CD008074-sec-0180"> <h4 class="title">3. COMPARISON 3. ARIPIPRAZOLE (intramuscular) versus OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular) </h4> <section id="CD008074-sec-0181"> <h5 class="title">3.1 Specific behaviour ‐ agitation</h5> <p>More participants allocated to olanzapine had an improvement in agitation at two hours (1 RCT, n = 80, RR 0.77, 95% CI 0.60 to 0.99, <i>low‐quality evidence;</i><a href="./references#CD008074-fig-0032" title="">Analysis 3.1</a>). Continuous measurements showed similar findings, results showing a favourable effect for olanzapine at two hours using ACES change scores (1 RCT, n = 80, MD 0.58, 95% CI 0.10 to 1.06) and PANSS‐EC change scores (1 RCT, n = 80, MD 3.30, 95% CI 1.25 to 5.35, <a href="./references#CD008074-fig-0033" title="">Analysis 3.2</a>). </p> </section> <section id="CD008074-sec-0182"> <h5 class="title">3.2 Global state</h5> <p>Olanzapine had a favourable effect compared to aripiprazole on global state when measured using CGI‐S change scores (1 RCT, n = 80, MD 0.58, 95% CI 0.01 to 1.15, <i>low‐quality evidence;</i><a href="./references#CD008074-fig-0034" title="">Analysis 3.3</a>). </p> </section> <section id="CD008074-sec-0183"> <h5 class="title">3.3 Adverse effects</h5> <section id="CD008074-sec-0184"> <h6 class="title">3.3.1 General</h6> <p>A comparable amount of participants in both groups experienced at least one adverse effect (1 RCT, n = 80, RR 0.75, 95% CI 0.45 to 1.24, <i>very low‐quality evidence;</i><a href="./references#CD008074-fig-0035" title="">Analysis 3.4</a>). No serious adverse events occurred (<a href="./references#CD008074-fig-0036" title="">Analysis 3.5</a>). </p> </section> <section id="CD008074-sec-0185"> <h6 class="title">3.3.2 Specific ‐ arousal</h6> <p>Significantly more participants allocated to olanzapine experienced somnolence during 24 hours (1 RCT, n = 80, RR 0.25, 95% CI 0.08 to 0.82, <i>low‐quality evidence</i>; <a href="./references#CD008074-fig-0037" title="">Analysis 3.6</a>). </p> </section> <section id="CD008074-sec-0186"> <h6 class="title">3.3.3 Specific ‐ cardiovascular</h6> <p>No significant differences were observed for systolic and diastolic pressure change from baseline, and for pulse rate change from baseline, both at two and 24 hours (<a href="./references#CD008074-fig-0038" title="">Analysis 3.7</a>). </p> </section> <section id="CD008074-sec-0187"> <h6 class="title">3.3.4 Specific ‐ movement disorders</h6> <p>Aripiprazole and olanzapine results were also similar for rigidity (1 RCT, n = 80, RR 1.33, 95% CI 0.32 to 5.58) and tremor (1 RCT, n = 80, RR 1.50, 95% CI 0.26 to 8.50) during 24 hours. None of the participants experienced akathisia or dystonia (<a href="./references#CD008074-fig-0039" title="">Analysis 3.8</a>), with similar continuous ratings for the former both at two hours (1 RCT, n = 80, MD ‐0.05, 95% CI ‐0.26 to 0.16) and at 24 hours (1 RCT, n = 80, MD ‐0.03, 95% CI ‐0.29 to 0.23, <a href="./references#CD008074-fig-0040" title="">Analysis 3.9</a>). </p> </section> <section id="CD008074-sec-0188"> <h6 class="title">3.3.5 Specific ‐ miscellaneous</h6> <p>Again, no effect was observed when aripiprazole and olanzapine were compared for headache (1 RCT, n = 80, RR 2.00, 95% CI 0.19 to 21.18), nausea (1 RCT, n = 80, RR 3.00, 95% CI 0.13 to 71.51), and pain at injection site (1 RCT, n = 80, RR 2.67, 95% CI 0.76 to 9.33), even though as regards the latter more events occurred in the aripiprazole group (<a href="./references#CD008074-fig-0041" title="">Analysis 3.10</a>). </p> </section> </section> <section id="CD008074-sec-0189"> <h5 class="title">3.4 Leaving the study early</h5> <p>None of the involved participants left this study early (<a href="./references#CD008074-fig-0042" title="">Analysis 3.11</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008074-sec-0190" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008074-sec-0190"></div> <section id="CD008074-sec-0191"> <h3 class="title" id="CD008074-sec-0191">Summary of main results</h3> <section id="CD008074-sec-0192"> <h4 class="title">1. COMPARISON 1. ARIPIPRAZOLE (intramuscular) versus PLACEBO/NIL</h4> <p>Two studies were included (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>; <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>), with a total number for this comparison of 382 participants (aripiprazole, n = 232; placebo, n = 150); available outcomes were rated of very low‐low quality evidence (<a href="./full#CD008074-tbl-0001">summary of findings Table for the main comparison</a>). No data concerning 'tranquillisation or asleep' and economic outcomes were available. </p> <section id="CD008074-sec-0193"> <h5 class="title">1.1 Repeated need for rapid tranquillisation, agitation</h5> <p>When compared to placebo, fewer people in the aripiprazole group required additional injections (<a href="./references#CD008074-fig-0006" title="">Analysis 1.1</a>). Significantly more participants in the aripiprazole group showed an at least 40% reduction in PANSS‐EC agitation score (<a href="./references#CD008074-fig-0007" title="">Analysis 1.2</a>) and <a href="./references#CD008074-fig-0008" title="">Analysis 1.3</a> showed higher improvement in agitation over continuous measurements, supporting potential benefits of this drug. However, outcomes for agitation were at two hours, a time point that meets only partially the issue of rapid tranquillisation. </p> </section> <section id="CD008074-sec-0194"> <h5 class="title">1.2 Global state</h5> <p>More people allocated to placebo failed to respond to the first injection and required additional benzodiazepines over 24 hours (<a href="./references#CD008074-fig-0009" title="">Analysis 1.4</a>); whilst the former statement is based on data from <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> only, the latter comes from the both included studies (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>; <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>). Continuous measurement scales (CGI‐I, CGI‐S) emphasise this outcome, with people in placebo group having worse rating scores (<a href="./references#CD008074-fig-0010" title="">Analysis 1.5</a>). </p> </section> <section id="CD008074-sec-0195"> <h5 class="title">1.3 Adverse effects ‐ any serious, specific adverse effects</h5> <p>Even though not formerly meeting statistical significance, a higher proportion of participants allocated to aripiprazole experienced one or more drug‐related adverse effects, and after the second injection more problems with adverse effects were recorded compared to people in the placebo group (<a href="./references#CD008074-fig-0012" title="">Analysis 1.7</a>). Adverse effects rated as serious were more common for participants allocated to aripiprazole, despite not meeting statistical significance (<a href="./references#CD008074-fig-0013" title="">Analysis 1.8</a>). </p> <p>When specific adverse effects were taken into account, a significant difference was observed only for the 'nausea during the 24 hours' outcome, more common in the aripiprazole group (<a href="./references#CD008074-fig-0017" title="">Analysis 1.12</a>); concerning the other adverse effects (insomnia, 'over'‐sedation, somnolence, dizziness, tachycardia, akathisia, dystonia, extrapyramidal symptoms , agitation, headache, pain at injection site, vomiting), recorded events were higher in the aripiprazole group, but statistical significance was not met (<a href="./references#CD008074-fig-0014" title="">Analysis 1.9</a>; <a href="./references#CD008074-fig-0015" title="">Analysis 1.10</a>; <a href="./references#CD008074-fig-0016" title="">Analysis 1.11</a>). However, it is important to consider that in both included studies (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>; <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>), data refer only to adverse effects that occurred in ≥ 5% of people. </p> </section> </section> <section id="CD008074-sec-0196"> <h4 class="title">2. COMPARISON 2. ARIPIPRAZOLE (intramuscular) versus OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular) </h4> <p>Data from a total number of 477 participants were extracted from included studies (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>; <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>, aripiprazole, n = 232; haloperidol, n = 245); the overall quality of the evidence was very low (<a href="./full#CD008074-tbl-0002">summary of findings Table 2</a>), suggesting caution in the interpretation of quantitative synthesis data. </p> <section id="CD008074-sec-0197"> <h5 class="title">2.1 Repeated need for rapid tranquillisation, agitation</h5> <p>Despite having comparable response rates and agitation rating scales at two hours (<a href="./references#CD008074-fig-0020" title="">Analysis 2.2</a>; <a href="./references#CD008074-fig-0021" title="">Analysis 2.3</a>), more participants allocated to aripiprazole required at least one additional injection during 24 hours (<a href="./references#CD008074-fig-0019" title="">Analysis 2.1</a>) when compared to haloperidol. Considering how difficult the management of repeated injections could be in an agitation setting and the potential distress of this for the user in need of tranquillisation, that use of haloperidol necessitates less injections is important. Direct data on tranquillisation were not available. </p> <p>Despite in both <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a> and <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a> it is stated that primary outcomes were recorded at multiple time points before two hours (0.5, 0.75, 1, 1.5 hours for <a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75 hours for <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>), no numeric data were available on related publications; two hours is a considerable amount of time after an acute aggressive or agitated event. </p> </section> <section id="CD008074-sec-0198"> <h5 class="title">2.2 Global state ‐ overall improvement</h5> <p>Proportions of non‐responders to the first injection between aripiprazole and haloperidol groups were comparable (<a href="./references#CD008074-fig-0022" title="">Analysis 2.4</a>), and so were the global outcome measurement scales (<a href="./references#CD008074-fig-0024" title="">Analysis 2.6</a>). </p> </section> <section id="CD008074-sec-0199"> <h5 class="title">2.3 Adverse effects ‐ any serious, specific adverse effects</h5> <p>Compared groups did not differ in terms of number of people that experienced at least one drug‐related adverse effect (<a href="./references#CD008074-fig-0025" title="">Analysis 2.7</a>); one person in the aripiprazole group had a tonic‐clonic seizure and one in the haloperidol group developed severe dystonia (<a href="./references#CD008074-fig-0026" title="">Analysis 2.8</a>). More participants allocated to haloperidol developed insomnia or, by contrast, were 'over'‐sedated during the 24 hours (<a href="./references#CD008074-fig-0027" title="">Analysis 2.9</a>), whilst nausea was significantly more common in the aripiprazole group (<a href="./references#CD008074-fig-0030" title="">Analysis 2.12</a>); with the exception of drug‐related movement disorders, that tended to be more common with haloperidol (<a href="./references#CD008074-fig-0029" title="">Analysis 2.11</a>), other adverse effects showed no differences between the compared groups (<a href="./references#CD008074-fig-0028" title="">Analysis 2.10</a>). </p> </section> <section id="CD008074-sec-0200"> <h5 class="title">2.4 Economic outcomes</h5> <p>No data concerning economic outcomes were available in the two included studies.</p> </section> </section> <section id="CD008074-sec-0201"> <h4 class="title">3. COMPARISON 3: ARIPIPRAZOLE (intramuscular) versus OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular) </h4> <p>One study was included (<a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>) with a total number of 80 participants (aripiprazole, n = 40; olanzapine, n = 40); outcomes were rated being of very low to low quality (<a href="./full#CD008074-tbl-0003">summary of findings Table 3</a>). No data concerning 'tranquillisation or asleep' and economic outcomes were available. </p> <section id="CD008074-sec-0202"> <h5 class="title">3.1 Agitation</h5> <p>As for participants allocated to aripiprazole, a significantly minor PANSS (Excited Component (PEC) response rate by two hours was observed (<a href="./references#CD008074-fig-0032" title="">Analysis 3.1</a>). Nevertheless, there are no outcomes available before two hours. </p> </section> <section id="CD008074-sec-0203"> <h5 class="title">3.2 Global state ‐ overall improvement</h5> <p>A significantly minor CGI‐S change score was observed for aripiprazole when compared to olanzapine, at two hours (<a href="./references#CD008074-fig-0034" title="">Analysis 3.3</a>). </p> </section> <section id="CD008074-sec-0204"> <h5 class="title">3.3 Adverse effects ‐ any serious, specific adverse effects</h5> <p>Compared groups did not differ in terms of number of people who experienced one or more drug‐related adverse effects (<a href="./references#CD008074-fig-0035" title="">Analysis 3.4</a>); no adverse events were rated as serious in both groups (<a href="./references#CD008074-fig-0036" title="">Analysis 3.5</a>). Aripiprazole and olanzapine results were comparable for all the investigated adverse events (<a href="./references#CD008074-fig-0038" title="">Analysis 3.7</a>; <a href="./references#CD008074-fig-0039" title="">Analysis 3.8</a>; <a href="./references#CD008074-fig-0040" title="">Analysis 3.9</a>; <a href="./references#CD008074-fig-0041" title="">Analysis 3.10</a>), with the exception of somnolence, which was more common in participants allocated to olanzapine (<a href="./references#CD008074-fig-0037" title="">Analysis 3.6</a>). Somnolence data at two hours could help to clarify if this issue could be a major PEC response rate of olanzapine. </p> </section> <section id="CD008074-sec-0205"> <h5 class="title">2.4 Economic outcomes</h5> <p>No data concerning economic outcomes were available.</p> </section> </section> </section> <section id="CD008074-sec-0206"> <h3 class="title" id="CD008074-sec-0206">Overall completeness and applicability of evidence</h3> <section id="CD008074-sec-0207"> <h4 class="title">1. Completeness</h4> <p>Data on several important questions are missing: satisfaction with care, acceptance of treatment, quality of life and economic outcomes. Current evidence‐based knowledge on aripiprazole in agitation is limited by the paucity of randomised controlled trials (RCTs) and low quality of available data, thus suggesting strong caution in the interpretation of results. </p> </section> <section id="CD008074-sec-0208"> <h4 class="title">2. Applicability</h4> <p>Two out of three of the currently available studies were undertaken in circumstances quite different from real clinical practice: involved participants constituted a specific population of voluntarily hospitalised patients that, while meeting specific agitation criteria for enrolment, "their level of agitation was not so pronounced that they could not give informed consent or participate in the study" (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>): this appears to be in line with the inclusion criteria applied in the two trials (<a href="./references#CD008074-bbs2-0001" title="AndrezinaR , JosiassenRC , MarcusRN , OrenDA , ManosG , StockE , et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double‐blind, placebo‐controlled comparison with intramuscular haloperidol. Psychopharmacology2006;188(3):281‐92. [EMBASE: 2006450840; MEDLINE: 0; MEDLINE: 16953381] AndrezinaR , MarcusRN , OrenDA , ManosG , StockE , CarsonWH , et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub‐analysis of a double‐blind study. Current Medical Research and Opinion2006;22(11):2209‐19. [EMBASE: 2006574726; MEDLINE: 17076982] Bristol‐MyersS . A randomized, double‐blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www.Clinicalstudyresults.org/2004. CitromeLL , Vester‐BloklandE , ArchibaldD , McQuadeR , KosticD , PikalovA , et al. Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. CurrierGW , CrandallD , ArchibaldD , NyilasM , KosticD , PikalovA , et al. Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006. DanielDG , CurrierGW , ZimbroffDL , AllenMH , OrenD , ManosG , et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of Psychiatric Practice2007;13(3):170‐7. [CINAHL: 2009612027; EMBASE: 2007257551; MEDLINE: 0; MEDLINE: 17522560; PsycINFO] DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. European Neuropsychopharmacology2005;15(Suppl.3):S509. DillenschneiderA , OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 18th European College of Neuropsychopharmacology Congress; 2005 October 22‐26, Amsterdam, Netherlands2005. McQuadeR , AubyP , OrenD , MarcusR , KosticD , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a double‐blind, placebo‐controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, Switzerland: Elsevier Science Bv, 2006:57‐8. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. OrenD , MarcusR , KosticD , McQuadeR , IwamotoT , ArchibaldD . Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophrenia Bulletin2005;31:499. [116266] OrenDA , MarcusRN , ManosG , CarsonWH , McQuadeD . Non‐inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophrenia Bulletin2007;33(2):451. YoccaF , MarcusR , OrenD , ManosG , CarsonW , IwamotoT , et al. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26, Atlanta, Georgia, USA2005. ">Andrezina 2006</a>; <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>), in which a PEC score ≥ 15 but ≤ 32 was requested. Participants in the included studies had their intervention delayed for screening and until deemed competent to give informed consent, a situation that is not common in the heat of an emergency and makes applicability problematic even if it is not impossible; it just necessitates a level of conjecture that could have been lessened had more pragmatic trials been available.<br/> <br/> While in <a href="./references#CD008074-bbs2-0003" title="KittipeerachonM , ChaichanW . Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double‐blind randomized trial. Schizophrenia Research2016;176(2‐3):231‐8. ">Kittipeerachon 2016</a>, a more pragmatic methodological design can be observed, generalisability of the outcomes is partly limited by the contrast between the lack of outcomes prior to two hours and the administration of a 'treatment as usual' during the 24 hours. </p> </section> </section> <section id="CD008074-sec-0209"> <h3 class="title" id="CD008074-sec-0209">Quality of the evidence</h3> <p>This review includes three trials completed over the last decade with a total sample size of 885 participants with schizophrenia, schizoaffective or schizophreniform disorder, of which 707 were included for quantitative analyses in this systematic review. Disappointingly, a proportion of interesting data were unusable, which could have been avoided had the trials been better reported. Overall, the majority of the evidence had to be graded as very low, usually because of considerable ‐ and often avoidable ‐ limits in research design, selective reporting and imprecision. </p> </section> <section id="CD008074-sec-0210"> <h3 class="title" id="CD008074-sec-0210">Potential biases in the review process</h3> <p>There are a number of ways in which bias could have been introduced into this review.</p> <section id="CD008074-sec-0211"> <h4 class="title">1. Trial selection and data extraction</h4> <p>For Cochrane reviews, at least two review authors independently inspect all citations obtained from the search and extract the data to minimise bias with a third completing a random sample check. This was achieved in the 2014 search but for the 2017 search only one review author inspected the search results and extracted data. However, the number of citations found in this search was low and in addition, to limit the possibility of this bias, screening obtained from the search was performed on two different occasions and compared. </p> </section> <section id="CD008074-sec-0212"> <h4 class="title">2. Review author conflict of interest</h4> <p>No conflict of interest is declared by the review authors.</p> </section> </section> <section id="CD008074-sec-0213"> <h3 class="title" id="CD008074-sec-0213">Agreements and disagreements with other studies or reviews</h3> <p>The authors are not aware of any other studies or reviews that have focused solely on use of aripiprazole IM alone for people who are aggressive secondary to serious mental illnesses. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008074-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Aripiprazole structure" data-id="CD008074-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Aripiprazole structure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (2014 search)." data-id="CD008074-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram (2014 search).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (2017 search)." data-id="CD008074-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram (2017 search).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008074-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008074-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 1 Repeated need for tranquillisation." data-id="CD008074-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 1 Repeated need for tranquillisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 2 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐EC reduction ≥ 40% from baseline)." data-id="CD008074-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 2 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐EC reduction ≥ 40% from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 3 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours." data-id="CD008074-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 3 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 4 Global state: 1. Various." data-id="CD008074-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 4 Global state: 1. Various. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 5 Global state: 2. Average scores ‐ i. up to 2 hours." data-id="CD008074-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 5 Global state: 2. Average scores ‐ i. up to 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 6 Mental state: 1. Average scores ‐ i. up to 2 hours." data-id="CD008074-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 6 Mental state: 1. Average scores ‐ i. up to 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 7 Adverse effects: 1a. General." data-id="CD008074-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 7 Adverse effects: 1a. General. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 8 Adverse effects: 1b. General ‐ serious." data-id="CD008074-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 8 Adverse effects: 1b. General ‐ serious. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 9 Adverse effects: 2a. Specific ‐ arousal." data-id="CD008074-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 9 Adverse effects: 2a. Specific ‐ arousal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 10 Adverse effects: 2b. Specific ‐ cardiovascular." data-id="CD008074-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 10 Adverse effects: 2b. Specific ‐ cardiovascular. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 11 Adverse effects: 2c. Specific ‐ movement disorders." data-id="CD008074-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 11 Adverse effects: 2c. Specific ‐ movement disorders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 12 Adverse effects: 2d. Specific ‐ miscellaneous." data-id="CD008074-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 12 Adverse effects: 2d. Specific ‐ miscellaneous. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 13 Leaving the study early." data-id="CD008074-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL, Outcome 13 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 1 Repeated need for tranquillisation." data-id="CD008074-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 1 Repeated need for tranquillisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 2 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐ EC reduction ≥ 40% from baseline)." data-id="CD008074-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 2 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐ EC reduction ≥ 40% from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 3 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours." data-id="CD008074-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 3 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 4 Global state: 1. Various." data-id="CD008074-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 4 Global state: 1. Various. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 5 Global outcome: 2. Average scores ‐ i. up to 2 hours." data-id="CD008074-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 5 Global outcome: 2. Average scores ‐ i. up to 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 6 Mental state: 1. Average scores ‐ i. up to 2 hours." data-id="CD008074-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 6 Mental state: 1. Average scores ‐ i. up to 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 7 Adverse effects: 1a. General." data-id="CD008074-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 7 Adverse effects: 1a. General. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 8 Adverse effects: 1b. General ‐ serious." data-id="CD008074-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 8 Adverse effects: 1b. General ‐ serious. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 9 Adverse effects: 2a. Specific ‐ arousal." data-id="CD008074-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 9 Adverse effects: 2a. Specific ‐ arousal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 10 Adverse effects: 2b. Specific ‐ cardiovascular." data-id="CD008074-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 10 Adverse effects: 2b. Specific ‐ cardiovascular. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 11 Adverse effects: 2c. Specific ‐ movement disorders." data-id="CD008074-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 11 Adverse effects: 2c. Specific ‐ movement disorders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 12 Adverse effects: 2d. Specific ‐ miscellaneous." data-id="CD008074-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 12 Adverse effects: 2d. Specific ‐ miscellaneous. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 13 Leaving the study early." data-id="CD008074-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular), Outcome 13 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 1 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐ EC reduction ≥ 40% from baseline)." data-id="CD008074-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 1 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐ EC reduction ≥ 40% from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 2 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours." data-id="CD008074-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 2 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 3 Global state: 1. Average scores ‐ i. up to 2 hours." data-id="CD008074-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 3 Global state: 1. Average scores ‐ i. up to 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 4 Adverse effects: 1a. General." data-id="CD008074-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 4 Adverse effects: 1a. General. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 5 Adverse effects: 1b. General ‐ serious." data-id="CD008074-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 5 Adverse effects: 1b. General ‐ serious. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 6 Adverse effects: 2a. Specific ‐ arousal." data-id="CD008074-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 6 Adverse effects: 2a. Specific ‐ arousal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 7 Adverse effects: 2b. Specific ‐ cardiovascular." data-id="CD008074-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 7 Adverse effects: 2b. Specific ‐ cardiovascular. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 8 Adverse effects: 2c. Specific ‐ movement disorders ‐ i. dichotomous." data-id="CD008074-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 8 Adverse effects: 2c. Specific ‐ movement disorders ‐ i. dichotomous. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 9 Adverse effects: 2d. Specific ‐ movement disorders ‐ ii. average scores." data-id="CD008074-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 9 Adverse effects: 2d. Specific ‐ movement disorders ‐ ii. average scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 10 Adverse effects: 2e. Specific ‐ miscellaneous." data-id="CD008074-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 10 Adverse effects: 2e. Specific ‐ miscellaneous. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008074-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/urn:x-wiley:14651858:media:CD008074:CD008074-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_t/tCD008074-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 11 Leaving the study early." data-id="CD008074-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular), Outcome 11 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/media/CDSR/CD008074/image_n/nCD008074-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008074-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for a trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, clearly described, concealed.<br/> Blindness: double, described and tested.<br/> Duration: 2 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: thought to be psychoses.<br/> N = 300.*<br/> Age: any.<br/> Sex: both. </p> <p>History: acutely ill, aggressive and/or agitated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Aripiprazole IM: dose flexible within recommended limits. N = 150.<br/> 2. Haloperidol IM: dose flexible within recommended limits. N = 150. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All outcomes are grouped by time: by 30 minutes, up to two hours, up to four hours, up to 24 hours, and over 24 hours. </p> <p>Tranquillisation or asleep ‐ tranquil; asleep.</p> <p>Repeated need for tranquillisation ‐ needing additional injections.<br/> Specific behaviours ‐ self‐harm, including suicide, injury to others.<br/> Global outcomes ‐ patient satisfaction; use of restraint or seclusion.<br/> Service outcomes ‐ length of hospitalisation; readmission rate.<br/> Mental state ‐ effect of medication on mental state.<br/> Adverse effects ‐ medication significant side effects.<br/> Leaving the study early ‐ detailed reasons provided. </p> <p>Quality of life outcomes.<br/> Economic outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of ˜20% between groups for primary outcome with adequate degree of certainty </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>IM: intramuscular</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for a trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008074-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Additional reviews relevant to aggression and suggested from excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Aripiprazole</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Combination</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison #1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison #2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Suggested title of review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cochrane review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short acting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aripiprazole + olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>quetiapine + olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0018" title="王琦 , 周丹 , 李萍 , 谢红涛 . 非典型抗精神病药对精神分裂症患者激越行为的随机对照研究. 中国健康心理学杂志2014;22(3):325‐7. ">Wang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipsychotic combinations for psychosis‐induced aggression or agitation (rapid tranquillisation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long acting (441mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long acting (882 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0014" title="CitromeL , DuY , RisingerR , StankovicS , ClaxtonA , ZummoJ , et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology2016;31(2):69‐75. CitromeL , DuY , RisingerR , StankovicS , ClaxtonA , ZummoJ , et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia: Erratum. International Clinical Psychopharmacology2017;32(1):56. HardM , StankovicS , RisingerR , BoseA , DuY , ZummoJ , et al. Efficacy of aripiprazole lauroxil, a new long‐acting injectable atypical antipsychotic, across three geographic regions. Neuropsychopharmacology2014;39:S359‐60. MeltzerHY , NasrallahHA , RisingerR , DuY , ZummoJ , CoreyL , et al. Aripiprazole lauroxil: an innovative long‐acting injectable in development for treatment of schizophrenia. 168th Annual Meeting of American Psychiatric Association; Toronto, Canada; May 16‐20, 2015. 2015. MeltzerHY , RisingerR , NasrallahHA , DuY , ZummoJ , CoreyL , et al. A randomized, double‐blind, placebo‐controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. Journal of Clinical Psychiatry2015;76(8):1085‐90. NCT01469039 . A study to evaluate the efficacy and safety of alks 9072 (also known as alks 9070) in subjects with schizophrenia. http://ClinicalTrials.gov/show/NCT014690392011. NasrallahHA , NewcomerJW , RisingerR , DuY , ZummoJ , BoseA , et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. Journal of Clinical Psychiatry2016;77(11):1519‐25. TargumSD , RisingerR , DuY , PendergrassJC , JamalHH , SilvermanBL . Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia [2017 Jan;179:64‐69.]. Schizophrenia Research2017;179:64‐9. ">NCT0146903</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole for long‐term aggression in psychosis; Placebo for long‐term aggression in psychosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aripiprazole + magnesium valproate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0010" title="李树生 . Aripiprazole for schizophrenia combined magnesium valproate efficacy of impulse control disorders] Google Translate [阿立哌唑联合丙戊酸镁对精神分裂症冲动控制障碍的疗效观察]. Chongqing Medical Journal2009;38(7):788‐9. ">Li 2009</a>, <a href="./references#CD008074-bbs2-0012" title="刘杰 . 丙戊酸镁对精神分裂症兴奋激越行为的辅助疗效观察. 社区医学杂志2012;10(14):31‐2. ">Liu 2012</a>, <a href="./references#CD008074-bbs2-0019" title="颉瑞 , 王刚平 , 裴根祥 . Clinical observation of magnesium valproate sustained release tablets adjuvant treatment of schizophrenia attacks [丙戊酸镁缓释片辅助治疗精神分裂症攻击行为的疗效观察]. 临床精神医学杂志2011;21(03):191‐2. ">Xie 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium valproate (+/‐aripiprazole) for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oral olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0005" title="陈远岭 , 黄文武 , 叶鑫武 . Aripiprazole treatment of agitation associated with schizophrenia] Google Translate [阿立哌唑治疗伴激越的精神分裂症对照研究 []. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(4):261‐2. ">Chen 2009</a>, <a href="./references#CD008074-bbs2-0009" title="EliLilly , Company . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry2004. KinonBJ , StaufferVL , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(6):601‐7. [MEDLINE: 19011427] NCT00103571 . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. http://www.clinicaltrials.gov2005. StaufferV , KinonB , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8, Washington DC, USA. 2008. [NR4‐109] ">Kinon 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole (oral) for psychosis‐induced aggression or agitation (rapid tranquillisation); Olanzapine (oral) for psychosis‐induced aggression or agitation (rapid tranquillisation); </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>? expansion of this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+ clonazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oral clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0004" title="BaoL‐Y , WangK‐M . The effectiveness of aripirazole combined with clonazepam treated with agitation in schizophrenia. Medical Journal of Chinese People's Health2007;19(3):198‐200. [CHINESE: Academic Journals] ">Bao 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aripiprazole plus benzodiazepines for psychosis‐induced aggression or agitation (rapid tranquillisation); Clozapine for psychosis‐induced aggression or agitation (rapid tranquillisation); </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>? expansion of this review; <a href="./references#CD008074-bbs2-0091" title="ToalF , RobertsK . Clozapine for people with psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012. ">Toal 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Non‐aripiprazole</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IM haloperidol + lorazepam + benztropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>oral quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0016" title="SimpsonG , MohammadAR , FauziaS , CampaneauM , LaskaE , NinahR , et al. A comparison of rapid titration quetiapine and haloperidol in agitated adults in an emergency setting. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. ">Simpson 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzodiazepines for psychosis‐induced aggression or agitation (rapid tranquillisation); Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation); Quetiapine for psychosis‐induced aggression or agitation (rapid tranquillisation) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0050" title="GilliesD , SampsonS , BeckA , RathboneJ . Benzodiazepines for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003079.pub3] ">Gillies 2015</a>;<a href="./references#CD008074-bbs2-0079" title="OstinelliEG , Brooke‐PowneyMJ , LiX , AdamsCE . Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews2017, Issue 7. [DOI: 10.1002/14651858.CD009377.pub3] ">Ostinelli 2017</a>;<a href="./references#CD008074-bbs2-0094" title="WilkieF , FentonM . Quetiapine for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009801] ">Wilkie 2012</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>* One sub‐study with people with aggression/agitation.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Additional reviews relevant to aggression and suggested from excluded studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008074-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to PLACEBO/NIL for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARIPIPRAZOLE compared to PLACEBO/NIL for psychosis‐induced aggression or agitation (rapid tranquillisation)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychosis‐induced aggression or agitation (rapid tranquillisation)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> ARIPIPRAZOLE (intramuscular)<br/> <b>Comparison:</b> PLACEBO/NIL </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PLACEBO/NIL</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ARIPIPRAZOLE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Repeated need for tranquillisation</b> ‐ needing additional injections during 24 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.69<br/> (0.56 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>382<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1.000<br/> (140 to 213) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414 per 1.000<br/> (336 to 510) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>518 per 1.000<br/> (420 to 638) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Specific behaviour:</b> Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 1.50<br/> (1.17 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>382<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1.000<br/> (117 to 192) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>525 per 1.000<br/> (410 to 672) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1.000<br/> (819 to 1.000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state:</b> non‐responders to the first injection </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.49<br/> (0.34 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>263<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1.000<br/> (68 to 142) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221 per 1.000<br/> (153 to 320) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>343 per 1.000<br/> (238 to 497) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects:</b> one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.51<br/> (0.93 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1.000<br/> (274 to 726) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'serious' (downgraded by 1) ‐ randomisation procedure is not reported for both the included studies, and allocation concealment procedure is not consistently reported in <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>. While for the 'randomisation' bias, studies are at least reported as 'randomised', as for the latter that allocation concealment was correctly handled could not be implied. </p> <p><sup>2</sup> Indirectness: rated 'very serious' (downgraded by 2) ‐ participants included in the studies had levels of agitation not so pronounced by inclusion criteria, potentially under‐estimating or more likely over‐estimating true effectiveness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to PLACEBO/NIL for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008074-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: a. HALOPERIDOL for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARIPIPRAZOLE compared to OTHER ANTIPSYCHOTIC: a. HALOPERIDOL for psychosis‐induced aggression or agitation (rapid tranquillisation)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychosis‐induced aggression or agitation (rapid tranquillisation)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> ARIPIPRAZOLE (intramuscular)<br/> <b>Comparison:</b> OTHER ANTIPSYCHOTIC: a. HALOPERIDOL </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ARIPIPRAZOLE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Repeated need for tranquillisation</b> ‐ needing additional injections during 24 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 1.28<br/> (1.00 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>477<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>,</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1.000<br/> (100 to 163) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>384 per 1.000<br/> (300 to 489) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>640 per 1.000<br/> (500 to 815) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Specific behaviour</b>: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.80 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>477<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 ,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>576 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1.000<br/> (460 to 639) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global state</b>: non‐responders to the first injection </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.78 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1.000<br/> (143 to 329) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects</b>: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/> (0.61 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>113<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>491 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1.000<br/> (300 to 663) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects</b>: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.29<br/> (0.12 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>471<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1.000<br/> (6 to 35) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1.000<br/> (12 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1.000<br/> (36 to 210) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'serious' (downgraded by 1) ‐ randomisation procedure is not reported for both the included studies, and allocation concealment procedure is not consistently reported in <a href="./references#CD008074-bbs2-0002" title='Bristol‐MyersSquibb . Randomized, double‐blind, dose‐ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder. http://www.clinicalstudyresults.org/2005. DanielDG , StockEG , WilberCH , MarcusRN , CarsonWHJr , ManosG , et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, New York, USA. 2004. GismondiR , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. European Neuropsychopharmacology2004;14(Suppl.3):S261. KungelM , CzanieraR , EbrechtM , WernerC , OrenD , McQuadeR , et al. Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double‐blind controlled study to find the dosage. Nervenarzt2007;78:77. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. Thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: an update". Florence, Italy, November 10‐13 2004. KungelM , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis. World Psychiatry2004;3(S1):218. ModellS , DanielD , StockE , WilberR , MarcusR , CarsonW , et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. XXIVth Collegium Internationale Neuro‐Psychopharmacologicum Congress; 2004 June 20–24, Paris, France2004. OrenDA , ManosG , MarkovicO , McQuadeRD . Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub‐analysis of a double‐blind, controlled, dose‐ranging study. European Psychiatry2007;22:S124‐S. Tran‐JohnsonTK , SackDA , MarcusRN , AubyP , McQuadeRD , OrenDA . Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(1):111‐9. [EMBASE: 2007077930; MEDLINE: 0; MEDLINE: 17284138; PsycINFO] YoccaF , DanielD , StockE , OrenD , MarcusR , CarsonW , et al. Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12‐16; San Juan, Puerto Rico. 2004. '>Bristol‐Myers 2005</a>. While for the 'randomisation' bias studies are at least reported as 'randomised', as for the latter that allocation concealment was correctly handled could not be implied. </p> <p><sup>2</sup> Indirectness: rated 'very serious' (downgraded by 2) ‐ participants included in the studies had levels of agitation not so pronounced by inclusion criteria, potentially under‐estimating or more likely over‐estimating true effectiveness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: a. HALOPERIDOL for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008074-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARIPIPRAZOLE compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE for psychosis‐induced aggression or agitation (rapid tranquillisation)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> psychosis‐induced aggression or agitation (rapid tranquillisation)<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> ARIPIPRAZOLE (intramuscular)<br/> <b>Comparison:</b> OTHER ANTIPSYCHOTIC: b. OLANZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with OTHER ANTIPSYCHOTIC: b. OLANZAPINE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ARIPIPRAZOLE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tranquillisation or asleep</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Repeated need for tranquillisation</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Specific behaviour:</b> Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.77<br/> (0.60 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1.000<br/> (300 to 495) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>616 per 1.000<br/> (480 to 792) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>693 per 1.000<br/> (540 to 891) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state:</b> CGI‐S change score up to 2 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.58<br/> (0.01 higher to 1.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects:</b> one or more adverse effects during 24 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/> (0.45 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1.000<br/> (225 to 620) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects:</b> somnolence during 24 hours </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.25<br/> (0.08 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>80<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1.000<br/> (8 to 82) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1.000<br/> (24 to 246) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1.000<br/> (56 to 574) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Economic outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Imprecision ‐ rated 'serious' (downgraded by 1): Optimal Information Size (OIS) criterion is not met meaning that imprecision of effect estimates could not be properly handled. </p> <p><sup>2</sup> Imprecision ‐ rated 'very serious' (downgraded by 2): Optimal Information Size (OIS) criterion is not met and CI overlaps no effect. High imprecision of effect estimates could not be properly excluded. </p> <p><sup>3</sup> Indirectness ‐ rated 'serious' (downgraded by 1): attribution to the intervention drugs is suspected but can not be confirmed since in the study results it is showed that almost all the participants were administered with 'treatment as usual' drugs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">ARIPIPRAZOLE (IM) compared to OTHER ANTIPSYCHOTIC: b. OLANZAPINE for psychosis‐induced aggression or agitation (rapid tranquillisation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008074-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other relevant Cochrane reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Focus of review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Completed and maintained reviews</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'As required' medication regimens for seriously mentally ill people in hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0043" title="Douglas‐HallP , WhicherEV . 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database of Systematic Reviews2015, Issue 12. [DOI: 10.1002/14651858.CD003441.pub3] ">Douglas‐Hall 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzodiazepines for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0050" title="GilliesD , SampsonS , BeckA , RathboneJ . Benzodiazepines for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003079.pub3] ">Gillies 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorpromazine for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0023" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2; PUBMED: 20393959] ">Ahmed 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotiapine for acute psychotic illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0029" title="BerkM , RathboneJ , Mandriota‐CarpenterSL . Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2] ">Berk 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Containment strategies for people with serious mental illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0076" title="MuralidharanS , FentonM . Containment strategies for people with serious mental illness. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD002084.pub2] ">Muralidharan 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>De‐escalation techniques for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0044" title="DuM , WangX , YinS , ShuW , HaoR , ZhaoS , et al. De‐escalation techniques for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD009922.pub2; CD009922] ">Du 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol for acute psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0063" title="KhokharMA , RathboneJ . Droperidol for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD002830.pub3] ">Khokhar 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol for long‐term aggression in psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0064" title="KhushuA , PowneyMJ . Haloperidol for long‐term aggression in psychosis. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2016, issue 11. [DOI: 10.1002/14651858.CD009830.pub2; CD009830] ">Khushu 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0079" title="OstinelliEG , Brooke‐PowneyMJ , LiX , AdamsCE . Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews2017, Issue 7. [DOI: 10.1002/14651858.CD009377.pub3] ">Ostinelli 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol plus promethazine for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0058" title="HufG , AlexanderJ , GandhiP , et al. Haloperidol plus promethazine for psychosis‐induced aggression. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD005146.pub3; CD005146] ">Huf 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0028" title="BelgamwarRB , FentonM . Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD003729.pub2] ">Belgamwar 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seclusion and restraint for serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0082" title="SailasE , FentonM . Seclusion and restraint for people with serious mental illnesses. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD001163] ">Sailas 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008074-bbs2-0060" title="JayakodyK , GibsonRC , KumarA , GunadasaS . Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD000525.pub3] ">Jayakody 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Reviews in the process of being completed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0024" title="AhmedU , RehmanF , JonesH , AdamsCE . Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD009412] ">Ahmed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loxapine inhaler for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0093" title="VangalaR , AhmedU , AhmedR . Loxapine inhaler for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD010190] ">Vangala 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine for people with psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0091" title="ToalF , RobertsK . Clozapine for people with psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012. ">Toal 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008074-bbs2-0094" title="WilkieF , FentonM . Quetiapine for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009801] ">Wilkie 2012</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other relevant Cochrane reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/full#CD008074-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008074-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Repeated need for tranquillisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 needing additional injections during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.56, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 needing 1 additional injection during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.69, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 needing 2 additional injections during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.19, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐EC reduction ≥ 40% from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 up to 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.17, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 change score (ABS, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.77 [‐5.39, ‐2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 change score (ACES, low=agitated, high=sedated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.15, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 change score (PANSS‐EC, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.49 [‐4.28, ‐0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 change score (PANSS‐EC, high=worse, schizophrenia subgroup)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.55 [‐3.78, ‐1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 change score (PANSS‐EC, high=worse, non‐sedated patients subgroup based on ACES)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.68 [‐3.75, ‐1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 change score (PANSS‐EC, high=worse, non‐sedated patients subgroup based on AEs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.83 [‐3.92, ‐1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 1. Various <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 non‐responders to the first injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.34, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 need for benzodiazepine up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.28, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 2. Average scores ‐ i. up to 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 endpoint score (CGI‐I, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐0.97, ‐0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 endpoint score (CGI‐I, high=worse, schizophrenia subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.17, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 change score (CGI‐S, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐0.86, ‐0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1. Average scores ‐ i. up to 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 change score up to 2 hours (BPRS total, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.39 [‐7.03, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 change score up to 2 hours (BPRS positive subscale, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.65, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1a. General <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 one or more drug related adverse events during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.93, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 onset or increased severity of adverse effects after 2nd injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [1.36, 4.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 1b. General ‐ serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 rated as serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.77 [0.63, 22.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 tonic clonic seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [0.14, 78.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 2a. Specific ‐ arousal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 insomnia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.25, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 "over" sedated during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.60, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 somnolence during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.57, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 2b. Specific ‐ cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 dizziness during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.66, 4.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 sinus tachycardia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 tachycardia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.36 [0.50, 37.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 2c. Specific ‐ movement disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 akathisia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.61 [0.40, 144.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 dystonia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [0.14, 78.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 EPS during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.06, 36.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 2d. Specific ‐ miscellaneous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 agitation during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.33, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 headache during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.74, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 pain at injection site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.30, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 nausea during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.97 [1.13, 13.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 vomiting during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.20, 23.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.35, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.07, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 withdrew consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.23, 12.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.25, 20.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.15, 7.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ARIPIPRAZOLE (intramuscular) vs PLACEBO/NIL</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008074-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Repeated need for tranquillisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 needing additional injections during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.00, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 needing 1 additional injection during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.66, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 needing 2 additional injections during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.77, 7.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐ EC reduction ≥ 40% from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 up to 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.80, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 change score (ABS, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [‐1.00, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 change score (ACES, low=agitated, high=sedated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.30, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 change score (PANSS‐EC, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [‐1.16, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 change score (PANSS‐EC, high=worse, schizophrenia subgroup)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.99, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 change score (PANSS‐EC, high=worse, non‐sedated patients subgroup based on ACES)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.82, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 change score (PANSS‐EC, high=worse, non‐sedated patients subgroup based on AEs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐0.68, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 1. Various <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 non‐responders to the first injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.78, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 need for benzodiazepine up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.46, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global outcome: 2. Average scores ‐ i. up to 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 endpoint score (CGI‐I, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.19, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 endpoint score (CGI‐I, high=worse, schizophrenia subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.44, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 change score (CGI‐S, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.36, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1. Average scores ‐ i. up to 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 change score up to 2 hours (BPRS total, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [‐1.70, 5.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 change score up to 2 hours (BPRS positive subscale, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.82, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1a. General <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 one or more drug related adverse events during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.61, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 onset or increased severity of adverse effects after 2nd injection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.57, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 1b. General ‐ serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 rated as serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.54, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 tonic clonic seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.13, 73.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 2a. Specific ‐ arousal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 insomnia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.23, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 "over" sedated during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.34, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 somnolence during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.41, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 2b. Specific ‐ cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 dizziness during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.66, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 sinus tachycardia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 tachycardia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.07 [0.47, 35.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 2c. Specific ‐ movement disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 akathisia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.13, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 dystonia during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 EPS during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 2d. Specific ‐ miscellaneous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 agitation during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.42, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 headache during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.62, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 pain at injection site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.75, 12.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 nausea during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.52 [1.63, 18.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 vomiting during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.19, 21.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.20, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.15, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 withdrew consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.10, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.18, 6.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.15, 3.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (intramuscular)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008074-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Specific behaviour: 1a. Agitation ‐ clinically important change (PANSS‐ EC reduction ≥ 40% from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 up to 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.60, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Specific behaviour: 1b. Agitation ‐ average scores ‐ i. up to 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 change score (ACES, low=agitated, high=sedated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.10, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 change score (PANSS‐EC, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [1.25, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 1. Average scores ‐ i. up to 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 change score (CGI‐S, high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.01, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: 1a. General <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 one or more drug related adverse events during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.45, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 1b. General ‐ serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 rated as serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 2a. Specific ‐ arousal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 somnolence during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.08, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 2b. Specific ‐ cardiovascular <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 systolic blood pressure change up to 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [‐6.77, 12.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 diastolic blood pressure change up to 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐8.09, 5.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 pulse rate change up to 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐6.80, 5.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 systolic blood pressure change up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [‐5.43, 12.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 diastolic blood pressure change up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐8.55, 5.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 pulse rate change up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.05 [‐13.43, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2c. Specific ‐ movement disorders ‐ i. dichotomous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 akathisia up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 dystonia up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 rigidity up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.32, 5.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 tremor up to 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.26, 8.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 2d. Specific ‐ movement disorders ‐ ii. average scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 SAS change score up to 2 hours (high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.26, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 SAS change score up to 24 hours (high=worse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.29, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 2e. Specific ‐ miscellaneous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 headache during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 pain at injection site during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.76, 9.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 nausea during 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ARIPIPRAZOLE (intramuscular) vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE (intramuscular)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008074.pub2/references#CD008074-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008074.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008074-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008074-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD008074-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008074-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008074-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008074\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008074\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008074\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008074\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008074\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008074.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008074.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008074.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008074.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008074.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719205599"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008074.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719205602"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008074.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de3111deb9368',t:'MTc0MDcxOTIwNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 